Astrazeneca PLC 6-K, filed Apr 29, 2022
Astrazeneca PLC (AZN)
6-K
2022-04-29
For: 2022-04-29
View Original
Added on
July 04, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on April 29, 2022.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
First quarter 2022
results
AstraZeneca PLC
29 April 2022 07:00 GMT
First quarter 2022 results
Strong start to the year. Continued investment in the
pipeline to drive sustainable long-term growth.
Revenue and EPS summary
|
|
|
|
Q1 2022
|
|
|
|
|
|
|
% Change
|
||
|
|
|
$m
|
Actual
|
CER1
|
|
|
- Product Sales
|
|
10,980
|
51
|
56
|
|
|
- Collaboration Revenue
|
|
410
|
n/m 2
|
n/m
|
|
|
Total Revenue
|
|
11,390
|
56
|
60
|
|
|
Reported3 EPS4
|
|
$0.25
|
(79)
|
(73)
|
|
|
Core5 EPS 6
|
|
$1.89
|
16
|
20
|
|
|
|
|
|
|
|
|
Financial performance (growth numbers at CER)
‒ Total
Revenue increased 60% to $11,390m, reflecting growth across the
Company, the contribution of the Alexion medicines and
several Vaxzevria contracts that are expected to complete
delivery by half year 2022
‒ Total
Revenue from Oncology increased 25%7,
including a milestone payment; Product Sales from Oncology
increased 18%. Total Revenue from CVRM8 increased
18%, R&I9 increased
4% and Rare Disease increased 7%10
‒ Operating
Margin in the quarter benefitted from phasing of
costs
‒ Core
EPS increased 20% to $1.89
‒ FY
2022 guidance at CER reiterated
Key milestones achieved since the prior results
‒ Key
data: Enhertu11 in
HER212-low
breast cancer (DESTINY-Breast04), AZD8233 in hypercholesterolaemia
(ETESIAN, Phase IIb) and publication of data
for Lynparza in prostate cancer (PROpel) and nirsevimab
in RSV13 (MELODY/MEDLEY)
‒ Key
approvals: Saphnelo and Evusheld in the EU, Ondexxya in Japan, and in the US, approvals
of Ultomiris for gMG14 and Lynparza15 for
early breast cancer (OlympiA)
‒ Other
key milestones: US FDA16 Breakthrough
Therapy Designation for Enhertu in HER2-low breast cancer
(DESTINY-Breast04), Priority Reviews for Enhertu in HER2-mutant metastatic non-small cell
lung cancer (DESTINY-Lung01), and Imfinzi and tremelimumab in advanced liver cancer
(HIMALAYA), and EMA17 accelerated
assessment for nirsevimab in RSV
(MELODY/MEDLEY)
Pascal Soriot, Chief Executive Officer, AstraZeneca,
said:
"2022 has started strongly for
AstraZeneca. Farxiga achieved
$1bn revenue in the quarter and our Oncology medicines delivered
Product Sales growth of 18%, despite COVID-19 continuing to impact
cancer diagnosis and treatment. High-level results from the
DESTINY-Breast04 trial pointed to Enhertu's potential to redefine treatment of HER2-low
metastatic breast cancer, and Ultomiris became the first and only long-acting C5
inhibitor approved for generalised myasthenia gravis in the
US.
Today we have unveiled plans for a new strategic research and
development centre in the heart of Cambridge, Massachusetts'
scientific hub. In line with our sustainability commitments,
it will be designed to the highest environmental standards. Our
investments in pioneering science give us confidence of further
advances in the years to come."
Guidance
The Company reiterates FY 2022 guidance at CER.
Total Revenue is expected to increase by a high teens
percentage
Core EPS is expected to increase by a mid-to-high twenties
percentage
‒ The
CER growth rates include the full-year contribution
of Vaxzevria in
both FY 2021 and FY 2022
‒ Total
Revenue from COVID-19 medicines is anticipated to decline by a
low-to-mid twenties percentage, with an expected decline in sales
of Vaxzevria being partially offset by growth
in Evusheld sales. The majority
of Vaxzevria revenue in 2022 is expected to come from
initial contracts. The Gross Margin from the COVID-19 medicines is
expected to be lower than the Company average
‒ Core
Operating Expenses are expected to increase by a low-to-mid teens
percentage, driven in substantial part by the full year integration
of Alexion expenses
‒ Emerging
Markets Total Revenue, including China, is expected to grow
mid-single-digits in FY 2022. China Total Revenue is expected to
decline by a mid-single-digit percentage in FY 2022, primarily due
to continued NRDL and VBP programme impacting various medicines.
The Company remains confident in the longer term outlook for
Emerging Markets, driven by a large market opportunity, broader
patient access and an increased mix of new
medicines
‒ A
Core Tax Rate between 18-22%
AstraZeneca continues to recognise and actively manage the
heightened risks from COVID-19 and geopolitical and supply chain
uncertainties on overall business performance. Variations in
performance between quarters can be expected to
continue.
The Company is unable to provide guidance on a Reported basis
because AstraZeneca cannot reliably forecast material elements of
the Reported result, including any fair value adjustments arising
on acquisition-related liabilities, intangible asset impairment
charges and legal-settlement provisions. Please refer to the
cautionary statements section regarding forward-looking statements
at the end of this announcement.
Currency impact
If foreign-exchange rates for April to December 2022 were to remain
at the average of rates seen in Q1 2022, it is anticipated that
there would be a low single-digit adverse impact on Total Revenue
and a mid single-digit adverse impact on Core EPS versus the
financials at CER. The Company's foreign-exchange rate sensitivity
analysis is contained in Table 15.
Table 1: Key elements of Total Revenue
performance
|
|
|
|
% Change
|
|
|
|||
|
Revenue type
|
|
$m
|
Actual
|
CER
|
|
|
||
|
Product Sales
|
|
10,980
|
51
|
56
|
|
$1,688m
from medicines acquired with Alexion
|
||
|
Collaboration Revenue
|
|
410
|
n/m
|
n/m
|
|
$76m for Enhertu (Q1 2021: $39m), and milestone payments of
$175m for Lynparza and $70m for tralokinumab (Q1 2021:
$nil)
|
||
|
Total Revenue
|
|
11,390
|
56
|
60
|
|
|
||
|
Disease areas
|
|
$m
|
Actual
|
CER
|
|
|
||
|
Oncology
|
|
3,644
|
21
|
25
|
|
Product
Sales up 14% (18% CER). Strong performance despite a continuing
COVID-19 impact on cancer diagnoses and
treatment rates
|
||
|
CVRM
|
|
2,219
|
14
|
18
|
|
Farxiga grew 60% (67% at CER) to
$1,001m
|
||
|
R&I
|
|
1,584
|
2
|
4
|
|
Pulmicort declined 34% primarily due to inclusion in
China's VBP18 programme,
implemented in October 2021
|
||
|
V&I19
|
|
1,814
|
20 >6x
|
>6x
|
|
$1,145m from Vaxzevria21 and
$469m from Evusheld
Majority of Vaxzevria revenue from initial contracts, several of
which completed during the quarter. In-line with
guidance, Vaxzevria revenue is expected to decline in later
quarters
|
||
|
Rare Disease
|
|
1,694
|
3
|
7
|
|
Durable C5 franchise growth, including continued
conversion from Soliris to Ultomiris in PNH22 and
aHUS23,
and Soliris growth in gMG and NMOSD24
|
||
|
Other Medicines
|
|
435
|
(18)
|
(15)
|
|
|
||
|
Total Revenue
|
|
11,390
|
56
|
60
|
|
|
||
|
Regions exc. Vaxzevria
|
|
$m
|
Actual
|
CER
|
|
|
||
|
Emerging Markets
|
|
2,833
|
11
|
14
|
|
|
||
|
- China
|
|
1,575
|
(6)
|
(8)
|
|
Pricing pressure associated with the
NRDL25 and
VBP programmes
|
||
|
- Ex-China Emerging Markets
|
|
1,258
|
45
|
57
|
|
$110m
from medicines acquired with Alexion
|
||
|
US
|
|
4,055
|
76
|
76
|
|
$1,014m
from medicines acquired with Alexion
|
||
|
Europe
|
|
2,150
|
63
|
73
|
|
$366m
from medicines acquired with Alexion
|
||
|
Established RoW
|
|
1,207
|
40
|
51
|
|
$208m
from medicines acquired with Alexion
|
||
|
Total Revenue exc. Vaxzevria
|
|
10,245
|
45
|
50
|
|
$1,698m
from medicines acquired with Alexion
|
||
|
Regions inc. Vaxzevria
|
|
$m
|
Actual
|
CER
|
|
|
||
|
Emerging Markets
|
|
3,364
|
30
|
32
|
|
Impacted by quarterly phasing
of Vaxzevria
|
||
|
- China
|
|
1,622
|
(3)
|
(6)
|
|
In
line with FY 2022 guidance
|
||
|
- Ex-China Emerging Markets
|
|
1,742
|
91
|
>2x
|
|
|
||
|
US
|
|
4,134
|
79
|
79
|
|
|
||
|
Europe
|
|
2,284
|
48
|
57
|
|
|
||
|
Established RoW
|
|
1,608
|
85
|
98
|
|
|
||
|
Total Revenue
|
|
11,390
|
56
|
60
|
|
|
||
|
|
|
|
|
|
|
|
|
|
Table 2: Key elements of financial performance
|
Q1 2022
|
|
|
||||
|
Metric($m or %)
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments26
|
|
Total Revenue
|
11,390
|
56% Actual 60% CER
|
11,390
|
56% Actual 60% CER
|
|
See
Table 1
|
|
Gross Margin27
|
68%
|
-6pp Actual-7pp CER
|
79%
|
+5pp Actual
+4pp CER
|
|
+
Contribution of Alexion
+
Increasing mix of Oncology sales
‒ Increasing
mix of COVID-19 therapies
‒ China
impact of NRDL and VBP
‒ Increasing
impact from profit-sharing arrangements including
the Lynparza collaboration with MSD
‒ Reported
impacted by unwind of Alexion inventory fair value
adjustment
|
|
R&D Expense
|
2,133
|
24% Actual 26% CER
|
2,186
|
33% Actual 36% CER
|
|
+
Increased investment in pipeline
+
Addition of Alexion R&D
‒ Beneficial
phasing of costs resulted in a Core R&D-to-Total Revenue ratio
of 19% (FY 2021: 21%)
|
|
SG&A Expense
|
4,840
|
65% Actual 68% CER
|
2,946
|
23% Actual 25% CER
|
|
+
Addition of Alexion
+
Reported impacted by $775m legal settlement with Chugai
Pharmaceutical Co. Ltd and amortisation related to Alexion
acquisition
‒ Beneficial
phasing of costs resulted in a Core SG&A-to-Total Revenue ratio
of 26% (FY 2021: 30%)
|
|
Other Operating Income28
|
97
|
(92%) Actual
(92%) CER
|
98
|
(92%) Actual (92%) CER
|
|
Limited
divestments in quarter, majority of income coming from royalties
and prior transactions
|
|
Operating Margin
|
8%
|
-18pp Actual-18pp CER
|
35%
|
Stable Actualand CER
|
|
See
Gross Margin and Expensescommentary above
|
|
Net Finance Expense
|
319
|
13% Actual 7% CER
|
252
|
35% Actual 23% CER
|
|
+
Alexion debt financing costs
‒ Reported
impacted by lower discount unwind on acquisition-related
liabilities
|
|
Tax Rate
|
30%
|
+27pp
|
21%
|
+13pp
|
|
In-line
with full year expectation of 18-22%
+
The Tax Rate in the comparable period of Q1 2021 was favourably
impacted by the disposal of Viela and settlements with tax
authorities
|
|
EPS
|
$0.25
|
(79%) Actual(73%) CER
|
$1.89
|
16% Actual 20% CER
|
|
Further
details of differences between Reported and Core are shown in Table
10
|
Corporate and business development
In April 2022, AstraZeneca and Harbour BioMed (HBM) committed to a
global out-license agreement for HBM7022, a pre-clinical bispecific
antibody targeting Claudin18.2 and CD3. AstraZeneca will be granted
an exclusive global license for research, development,
registration, manufacturing, and commercialisation of
HBM7022.
HBM shall receive an upfront payment of $25m with the potential for
additional payments up to $325m pending achievement of certain
development, regulatory and commercial milestones. HBM is also
eligible to receive tiered royalties on net sales.
Sustainability summary
AstraZeneca published its eighth annual Sustainability
Report and Sustainability
Data summary, released in conjunction with the 2021 Annual Report.
The report outlines progress on strategic priorities, material
focus areas, challenges and aims for the
future.
AstraZeneca continues to provide urgent humanitarian support in
Ukraine and neighbouring countries. To date, AstraZeneca has
committed over $7m to response efforts, including donations
of:
‒ Medicines to the
Company's humanitarian relief partner Direct Relief, which is
working directly with the Ukrainian Ministry of
Health
‒ Medicines
via The Red Cross affiliates in neighbouring
countries
‒ $2m
to support relief agencies working in Ukraine, Poland and
surrounding areas with a focus on providing healthcare and
humanitarian assistance. Funding is being provided to Project HOPE,
working with and through the World Health Organization, and
International Medical Corps
‒ More
than $1m to UNICEF and The Red Cross
Reporting changes for Q1 2022
AstraZeneca's Total Revenue and Product Sales tables in FY 2022
include a new disease area: BioPharmaceuticals: Vaccines &
Immune Therapies (V&I). This incorporates revenues
from Vaxzevria, Evusheld, FluMist, Synagis and nirsevimab. In the FY 2021 quarterly and
annual reports, Vaxzevria and Evusheld revenues were shown under COVID-19,
and FluMist, Synagis and nirsevimab revenues were shown under
Other Medicines. In addition, revenue from Koselugo have moved from Oncology to Rare Disease,
and revenue from Andexxa has moved from Rare Disease to
BioPharmaceuticals: CVRM.
The growth rate for each disease area has been calculated as though
these changes had been implemented in FY 2021.
Conference call
A conference call and webcast for investors and analysts will begin
today (29 April 2022) at 11:45 BST. Details can be accessed via
astrazeneca.com.
Reporting calendar
The Company intends to publish its half-year and second-quarter
results on Friday 29 July 2022.
Notes
The following notes refer to pages one to five.
1.
Constant exchange rates. The differences between Actual Change and
CER Change are due to foreign exchange movements between periods in
2022 vs 2021. CER financial measures are not accounted for
according to generally accepted accounting principles (GAAP)
because they remove the effects of currency movements from Reported
results.
2.
Not meaningful
3.
Reported financial measures are the financial results presented in
accordance with UK-adopted International Accounting Standards and
International Financial Reporting Standards (IFRSs) as issued by
the International Accounting Standards Board (IASB) and
International Accounting Standards as adopted by the European
Union.
4.
Earnings per share.
5.
Core financial measures. These are non-GAAP financial measures
because, unlike Reported performance, they cannot be derived
directly from the information in the Group's Financial Statements.
See the Operating and financial review for a definition of Core
financial measures and a reconciliation of Core to Reported
financial measures.
6.
The differences between Reported and Core measures are primarily
due to items related to the acquisition of Alexion, amortisation of
intangibles, impairments, restructuring charges, and, as previously
disclosed, a charge to provisions relating to a legal settlement
with Chugai Pharmaceutical Co. Ltd that will lead to a payment of
$775m in the Q2 2022. A full reconciliation between Reported EPS
and Core EPS is provided in Table 10 in the Financial performance
section of this document.
7. In FY 2022, Total Revenue
from Koselugo is included in Rare Disease (FY 2021:
Oncology), and Total Revenue from Andexxa is included in BioPharmaceuticals: CVRM (FY
2021: Rare Disease). The growth rate for each disease area has been
calculated as though these changes had been implemented in FY
2021.
8.
Cardiovascular, Renal & Metabolism.
9.
Respiratory & Immunology.
10.
FY 2022 Q1 growth rates on medicines acquired with Alexion have
been calculated on a pro forma basis comparing to the corresponding
period in the prior year, pre-acquisition as previously published
by Alexion. The growth rates shown for the Rare Disease and CVRM
disease areas include these pro forma adjustments.
11. AstraZeneca is collaborating with
Daiichi Sankyo to develop and
commercialise Enhertu.
12.
Human epidermal growth factor receptor 2.
13.
Respiratory syncytial virus.
14.
Generalised myasthenia gravis.
15. AstraZeneca is collaborating with MSD
(Merck & Co., Inc. in the US and Canada) to develop and
commercialise Lynparza.
16.
US Food and Drug Administration.
17.
European Medicines Agency.
18.
Volume based procurement.
19.
Vaccines & Immune Therapies.
20.
Growth rates greater than 100% are displayed as a multiple, for
example Ô>2x' signifies that the value is more than double
that of the comparable period
21. Vaxzevria is AstraZeneca's trademark for the Company's
supply of the AstraZeneca COVID-19 Vaccine. In the financial tables
in this report, 'Vaxzevria Total Revenue' includes Collaboration
Revenue from sub-licensees that produce and supply the AstraZeneca
COVID-19 Vaccine under their own trademarks.
22.
Paroxysmal nocturnal haemoglobinuria.
23.
Atypical haemolytic uraemic syndrome.
24.
Neuromyelitis optica spectrum disorder.
25.
National Reimbursement Drug List.
26.
The plus and minus signs in Table 2 indicate the directional impact
of the item being discussed, e.g. a plus sign in R&D Expenses
signifies that the comment refers to an item that increased the
R&D Expense relative to the prior year.
27.
Gross Profit is defined as Total Revenue minus Cost of Sales. The
calculation of Reported and Core Gross Margin excludes the impact
of Collaboration Revenue and any associated costs, thereby
reflecting the underlying performance of Product
Sales.
28.
Where AstraZeneca does not retain a significant ongoing interest in
medicines or potential new medicines, income from divestments is
reported within Reported and Core Other Operating Income and
Expense in the Company's financial statements.
Pipeline
Table 3: Pipeline highlights since prior results
announcement
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
|
|
Lynparza
|
gBRCA[29] breast
cancer (adjuvant) (OlympiA)
|
Regulatory approval (US)
|
|
Regulatory
approvals and
other regulatory
actions
|
Saphnelo
|
SLE[30]
|
Regulatory approval (EU)
|
|
Ondexxya
|
Acute major bleed
|
Regulatory approval (JP)
|
|
|
Evusheld
|
COVID-19 pre-exposure prophylaxis (PROVENT)
|
Regulatory approval (EU)
|
|
|
|
Ultomiris
|
gMG (CHAMPION-MG)
|
Regulatory approval (US)
|
|
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory submission (JP)
|
|
|
Imfinzi +
tremelimumab
|
Advanced liver cancer (1st-line) (HIMALAYA)
|
Priority review (US), regulatory submission (EU, JP)
|
|
|
Lynparza
|
Prostate cancer (1st-line) (PROpel)
|
Regulatory submission (JP)
|
|
Regulatory
submissions or
acceptances
|
Enhertu
|
HER2m NSCLC[31] (2nd-line+)
(DESTINY-Lung01)
|
Priority review (US)
|
|
Calquence
|
CLL[32] (ELEVATE-TN)
|
Regulatory submission (JP)
|
|
|
|
nirsevimab
|
RSV (MELODY/MEDLEY)
|
Regulatory submission and EMA accelerated assessment
(EU)
|
|
|
Evusheld
|
COVID-19 outpatient treatment (TACKLE)
|
Regulatory submission (US, EU)
|
|
|
Ultomiris
|
Subcutaneous, PNH and aHUS
|
Regulatory submission (EU)
|
|
|
Imfinzi
|
Cervical cancer (CALLA)
|
Primary endpoint not met
|
|
Major Phase III
data readouts
and other
developments
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Orphan Drug Designation (JP)
|
|
Enhertu
|
HER2+ breast cancer (2nd-line) (DESTINY-Breast03)
|
Breakthrough Drug Designation (CN)
|
|
|
Enhertu
|
HER2-low breast cancer(DESTINY-Breast04)
|
Primary endpoint met, Breakthrough Drug Designation,
RTOR[33] (US)
|
|
|
|
Fasenra
|
Nasal polyps (OSTRO)
|
Complete response letter (US)
|
|
|
Brilinta
|
|
Paediatric exclusivity (US)
|
Table 4: Pipeline anticipated major news flow
|
Timing
|
Medicine
|
Indication / Trial
|
Event
|
|
H1 2022
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory submission (US, EU)
|
|
|
Lynparza
|
Prostate cancer (1st-line) (PROpel)
|
Regulatory submission (US)
|
|
|
Enhertu
|
HER2+ breast cancer (2nd-line) (DESTINY-Breast03)
|
Regulatory decision (US), regulatory submission (CN)
|
|
|
Enhertu
|
HER2-low breast cancer (3rd-line) (DESTINY-Breast04)
|
Regulatory submission
|
|
|
Forxiga
|
CKD[34] (DAPA-CKD)
|
Regulatory decision (CN)
|
|
|
Farxiga
|
HFpEF[35] (DELIVER)
|
Data readout
|
|
|
eplontersen
|
hATTR-PN[36] (NEURO-TTRansform)
|
Data readout[37]
|
|
|
Brilinta
|
Stroke (THALES)
|
Regulatory decision (CN)
|
|
|
Tezspire
|
Severe asthma (NAVIGATOR)
|
Regulatory decision (EU, JP)
|
|
|
PT027
|
Asthma
|
Regulatory submission (US)
|
|
|
Evusheld
|
COVID-19 outpatient treatment (EU)
|
Regulatory decision (EU)
|
|
|
Vaxzevria
|
COVID-19
|
Regulatory submission (US)
|
|
|
Ultomiris
|
NMOSD
|
Data readout
|
|
H2 2022
|
Tagrisso
|
EGFRm NSCLC (adjuvant) (ADAURA)
|
Regulatory decision (JP)
|
|
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory decision
|
|
|
Imfinzi
|
Liver cancer (locoregional)(EMERALD-1)
|
Data readout, regulatory submission
|
|
|
Imfinzi
|
NSCLC (1st-line) (PEARL)
|
Data readout
|
|
|
Imfinzi
|
NSCLC (unresectable, Stg. III) (PACIFIC-2)
|
Data readout
|
|
|
Imfinzi
|
Limited-stage SCLC (ADRIATIC)
|
Data readout
|
|
|
Imfinzi +/-
tremelimumab
|
NSCLC (1st-line) (POSEIDON)
|
Regulatory decision
|
|
|
Imfinzi +/-
tremelimumab
|
Liver cancer (1L) (HIMALAYA)
|
Regulatory decision
|
|
|
Lynparza
|
gBRCA breast cancer (adjuvant) (OlympiA)
|
Regulatory decision (EU, JP)
|
|
|
Lynparza
|
Ovarian cancer (1st-line) (PAOLA-1)
|
Regulatory decision (CN)
|
|
|
Lynparza
|
Prostate cancer (1st-line) (PROpel)
|
Regulatory decision
|
|
|
Enhertu
|
HER2+ breast cancer (3rd-line) (DESTINY-Breast02)
|
Data readout, regulatory submission
|
|
|
Enhertu
|
HER2+ breast cancer (2nd-line) (DESTINY-Breast03)
|
Regulatory decision (EU, JP)
|
|
|
Enhertu
|
HER2+ gastric cancer (2nd-line) (DESTINY-Gastric01)
|
Regulatory decision (EU)
|
|
|
Enhertu
|
HER2m NSCLC (2nd-line+)(DESTINY-Lung01)
|
Regulatory decision
|
|
|
capivasertib
|
HR+/HER2-neg breast cancer (1st-line) (CAPItello-291)
|
Data readout
|
|
|
Farxiga
|
HFpEF (DELIVER)
|
Regulatory submission
|
|
|
eplontersen
|
hATTR-PN
|
Regulatory submission (US)
|
|
|
Fasenra
|
EOE[38] (MESSINA)
|
Data readout
|
|
|
nirsevimab
|
RSV (MELODY/MEDLEY)
|
Regulatory submission (US) and regulatory decision
|
|
|
Evusheld
|
COVID-19 (TACKLE/PROVENT)
|
Regulatory submission (JP, CN)
|
|
|
Evusheld
|
COVID-19 outpatient treatment (TACKLE)
|
Regulatory decision
|
|
|
Utomiris
|
gMG (CHAMPION-MG)
|
Regulatory decision (EU, JP)
|
|
|
Ultomiris
|
Subcutaneous, PNH and aHUS
|
Regulatory decision
|
|
|
Ultomiris
|
NMOSD
|
Regulatory submission
|
|
|
Koselugo
|
NF1-PN (SPRINT)
|
Regulatory submission (CN), regulatory decision (JP)
|
|
2023
|
Tagrisso
|
EGFRm[39] NSCLC
(1st-line) (FLAURA2)
|
Data readout, regulatory submission
|
|
|
Tagrisso
|
EGFRm NSCLC (unresectable Stg. III) (LAURA)
|
Data readout, regulatory submission
|
|
|
Imfinzi
|
Bladder cancer (muscle invasive) (NIAGARA)
|
Data readout, regulatory submission
|
|
|
Imfinzi
|
Bladder cancer (1st-line) (NILE)
|
Data readout, regulatory submission
|
|
|
Imfinzi
|
NSCLC (neoadjuvant) (AEGEAN)
|
Data readout, regulatory submission
|
|
|
Imfinzi
|
Liver cancer (adjuvant) (EMERALD-2)
|
Data readout, regulatory submission
|
|
|
Imfinzi
|
NSCLC (unresectable, Stg. III) (PACIFIC-2)
|
Regulatory submission
|
|
|
Imfinzi
|
NSCLC (1st-line) (PEARL)
|
Regulatory submission
|
|
|
Imfinzi
|
Limited-stage SCLC (ADRIATIC)
|
Regulatory submission
|
|
|
Lynparza
|
gBRCA breast cancer (adjuvant) (OlympiA)
|
Regulatory submission (CN)
|
|
|
Lynparza + Imfinzi
|
Endometrial cancer (1st-line) (DUO-E)
|
Data readout
|
|
|
Lynparza + Imfinzi
|
Ovarian cancer (1st-line) (DUO-O)
|
Data readout
|
|
|
Enhertu
|
HER2-low breast cancer (2nd-line) (DESTINY-Breast06)
|
Data readout
|
|
|
Calquence
|
CLL (ELEVATE-TN)
|
Regulatory decision (JP)
|
|
|
Calquence
|
CLL (ACE-CL-311)
|
Data readout
|
|
|
Calquence
|
MCL[40] (1st-line)
(ECHO)
|
Data readout
|
|
|
capivasertib
|
TNBC[41] (locally
adv./met.)(CAPItello-290)
|
Data readout, regulatory submission
|
|
|
capivasertib
|
HR+/HER2-neg breast cancer (1st-line) (CAPItello-291)
|
Regulatory submission
|
|
|
camizestrant
|
HR+/HER2-neg breast cancer (SERENA-6)
|
Data readout
|
|
|
Dato-DXd
|
NSCLC (3rd-line) (TROPION-Lung01)
|
Data readout, regulatory submission
|
|
|
Farxiga
|
Myocardial infarction (DAPA-MI)
|
Data readout
|
|
|
roxadustat
|
Anaemia of myelodysplastic syndrome
|
Data readout
|
|
|
Fasenra
|
Bullous pemphigoid (FJORD)
|
Data readout
|
|
|
Fasenra
|
CRwNP[42] (ORCHID)
|
Data readout
|
|
|
Fasenra
|
EGPA[43] (MANDARA)
|
Data readout
|
|
|
Fasenra
|
EOE (MESSINA)
|
Regulatory submission
|
|
|
Fasenra
|
HES (NATRON)
|
Data readout
|
|
|
Fasenra
|
Severe asthma (MIRACLE)
|
Data readout
|
|
|
nirsevimab
|
RSV (MELODY/MEDLEY)
|
Regulatory submission (JP, CN)
|
|
|
Soliris
|
Guillain-Barre syndrome
|
Data readout
|
|
|
ALXN1840
|
Wilson disease
|
Regulatory submission
|
|
|
danicopan
|
PNH with extravascular haemolysis
|
Data readout, regulatory submission
|
Operating and financial review
All narrative on growth and results in this section is based on
actual exchange rates, and financial figures are in US$ millions
($m), unless stated otherwise. The performance shown in this
announcement covers the three-month period to 31 March 2022
(Ôthe quarter' or ÔQ1 2022') compared to the three-month
period to 31 March 2021 (Q1 2021), unless stated
otherwise.
Core financial measures, EBITDA, Net Debt, Initial Collaboration
Revenue and Ongoing Collaboration Revenue are non-GAAP financial
measures because they cannot be derived directly from the Group's
Interim Financial Statements. Management believes that these
non-GAAP financial measures, when provided in combination with
Reported results, provide investors and analysts with helpful
supplementary information to understand better the financial
performance and position of the Group on a comparable basis from
period to period. These non-GAAP financial measures are not a
substitute for, or superior to, financial measures prepared in
accordance with GAAP.
Core financial measures are adjusted to exclude certain significant
items, such as:
‒ Amortisation
and impairment of intangible assets, including impairment reversals
but excluding any charges relating to IT assets
‒ Charges
and provisions related to restructuring programmes, which includes
charges that relate to the impact of restructuring programmes on
capitalised IT assets as well as Post Alexion Acquisition Group
Review items
‒ Alexion
acquisition-related items, primarily fair-value adjustments on
acquired inventories and fair-value impact of replacement employee
share awards
‒ Other
specified items, principally the imputed finance charge relating to
contingent consideration on business combinations and legal
settlements
Details on the nature of Core financial measures are provided on
page 54 of the Annual Report and Form
20-F Information 2021.
Reference should be made to the Reconciliation of Reported to Core
financial measures table included in the financial performance
section in this announcement.
Gross Margin, previously termed Gross Profit Margin, is the
percentage by which Product Sales exceeds the Cost of sales,
calculated by dividing the difference between the two by the sales
figure. The calculation of Reported and Core Gross Margin excludes
the impact of Collaboration Revenue and any associated costs,
thereby reflecting the underlying performance of Product
Sales.
EBITDA is defined as Reported Profit Before Tax after adding back
Net Finance Expense, results from Joint Ventures and Associates and
charges for Depreciation, Amortisation and Impairment. Reference
should be made to the Reconciliation of Reported Profit Before Tax
to EBITDA included in the financial performance section in this
announcement.
Net Debt is defined as Interest-bearing loans and borrowings and
Lease liabilities, net of Cash and cash equivalents, Other
investments, and net derivative financial instruments. Reference
should be made to Note 3 ÔNet Debt' included in the Notes to
the Interim Financial Statements in this announcement.
Ongoing Collaboration Revenue is defined as Collaboration Revenue
excluding Initial Collaboration Revenue (which is defined as
Collaboration Revenue that is recognised at the date of completion
of an agreement or transaction, in respect of upfront
consideration). Ongoing Collaboration Revenue comprises, among
other items, royalties, milestone revenue and profit-sharing
income. Reference should be made to the Collaboration Revenue table
in this Operating and financial review.
The Company strongly encourages investors and analysts not to rely
on any single financial measure, but to review AstraZeneca's
financial statements, including the Notes thereto, and other
available Company reports, carefully and in their
entirety.
Due to rounding, the sum of a number of dollar values and
percentages may not agree to totals.
Total Revenue
Table 5: Disease area and medicine performance
|
|
|
Q1 2022
|
|||
|
|
|
|
|
% Change
|
|
|
Product Sales
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
|
3,388
|
30
|
14
|
18
|
|
- Tagrisso
|
|
1,304
|
11
|
14
|
17
|
|
- Imfinzi
|
|
599
|
5
|
8
|
11
|
|
- Lynparza
|
|
617
|
5
|
14
|
17
|
|
- Calquence
|
|
414
|
4
|
98
|
100
|
|
- Enhertu
|
|
11
|
-
|
>9x
|
>9x
|
|
- Orpathys
|
|
13
|
-
|
n/m
|
n/m
|
|
- Zoladex
|
|
240
|
2
|
9
|
12
|
|
- Faslodex
|
|
93
|
1
|
(24)
|
(20)
|
|
- Iressa
|
|
32
|
-
|
(47)
|
(47)
|
|
- Arimidex
|
|
32
|
-
|
(27)
|
(25)
|
|
- Casodex
|
|
21
|
-
|
(48)
|
(47)
|
|
- Others
|
|
12
|
-
|
1
|
6
|
|
BioPharmaceuticals: CVRM
|
|
2,207
|
19
|
14
|
17
|
|
- Farxiga
|
|
1,000
|
9
|
60
|
67
|
|
- Brilinta
|
|
325
|
3
|
(13)
|
(10)
|
|
- Lokelma
|
|
63
|
1
|
92
|
97
|
|
- Roxadustat
|
|
41
|
-
|
6
|
4
|
|
- Andexxa10
|
|
33
|
-
|
13
|
14
|
|
- Crestor
|
|
267
|
2
|
(2)
|
-
|
|
- Seloken/Toprol-XL
|
|
244
|
2
|
(2)
|
(1)
|
|
- Bydureon
|
|
68
|
1
|
(34)
|
(33)
|
|
- Onglyza
|
|
68
|
1
|
(33)
|
(31)
|
|
- Others
|
|
98
|
1
|
(15)
|
(13)
|
|
BioPharmaceuticals: R&I
|
|
1,509
|
13
|
(2)
|
-
|
|
- Symbicort
|
|
674
|
6
|
(2)
|
-
|
|
- Fasenra
|
|
308
|
3
|
18
|
22
|
|
- Breztri
|
|
87
|
1
|
>3x
|
>3x
|
|
- Saphnelo
|
|
11
|
-
|
n/m
|
n/m
|
|
- Pulmicort
|
|
217
|
2
|
(34)
|
(34)
|
|
- Daliresp
|
|
51
|
-
|
(16)
|
(16)
|
|
- Bevespi
|
|
15
|
-
|
15
|
14
|
|
- Others
|
|
146
|
1
|
(9)
|
(9)
|
|
BioPharmaceuticals: V&I
|
|
1,757
|
15
|
>5x
|
>6x
|
|
- Vaxzevria
|
|
1,089
|
10
|
>3x
|
>4x
|
|
- Evusheld
|
|
469
|
4
|
n/m
|
n/m
|
|
- Synagis
|
|
200
|
2
|
>8x
|
>8x
|
|
- FluMist
|
|
(1)
|
-
|
n/m
|
n/m
|
|
Rare Disease10
|
|
1,694
|
15
|
3
|
7
|
|
- Soliris10
|
|
990
|
9
|
(5)
|
-
|
|
- Ultomiris10
|
|
419
|
4
|
20
|
25
|
|
- Strensiq10
|
|
208
|
2
|
5
|
7
|
|
- Koselugo
|
|
39
|
-
|
82
|
85
|
|
- Kanuma10
|
|
38
|
-
|
9
|
15
|
|
Other Medicines
|
|
425
|
4
|
(19)
|
(15)
|
|
- Nexium
|
|
332
|
3
|
(18)
|
(13)
|
|
- Others
|
|
93
|
1
|
(22)
|
(22)
|
|
Product Sales
|
|
10,980
|
96
|
51
|
56
|
|
Collaboration Revenue
|
|
410
|
4
|
n/m
|
n/m
|
|
Total Revenue
|
|
11,390
|
100
|
56
|
60
|
Table 6: Collaboration Revenue
|
|
|
Q1 2022
|
|||
|
|
|
|
|
% Change
|
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Lynparza: milestone
revenue
|
|
175
|
43
|
n/m
|
n/m
|
|
Enhertu: share of gross
profits
|
|
75
|
18
|
96
|
96
|
|
Royalty income
|
|
73
|
18
|
n/m
|
n/m
|
|
Tralokinumab: sales milestones
|
|
70
|
17
|
n/m
|
n/m
|
|
Other Collaboration Revenue
|
|
17
|
4
|
n/m
|
n/m
|
|
Total
|
|
410
|
100
|
n/m
|
n/m
|
Table 7: Total Revenue by region
|
|
|
Q1 2022
|
|||
|
|
|
|
% of
|
% Change
|
|
|
|
|
$m
|
Total
|
Actual
|
CER
|
|
Emerging Markets
|
|
3,364
|
30
|
30
|
32
|
|
- China
|
|
1,622
|
14
|
(3)
|
(6)
|
|
- Ex-China
|
|
1,742
|
15
|
91
|
>2x
|
|
US
|
|
4,134
|
36
|
79
|
79
|
|
Europe
|
|
2,284
|
20
|
48
|
57
|
|
Established RoW
|
|
1,608
|
14
|
85
|
98
|
|
Total
|
|
11,390
|
100
|
56
|
60
|
Oncology
Total Revenue increased by 21% (25% at CER) in Q1 2022 to $3,644m
and represented 32% of overall Total Revenue (Q1 2021: 41%). This
included Lynparza Collaboration Revenue of $175m
and Enhertu Collaboration Revenue of $76m. Product Sales
increased by 14% (18% at CER) in Q1 2022 to $3,388m, reflecting new
launches and increased patient access for Tagrisso, Imfinzi, Lynparza, Calquence and Enhertu partially offset by declines in legacy
medicines and an adverse gross-to-net[44] movement
from the seasonal increase in Part-D related deductions typically
seen in the first quarter.
Tagrisso
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
1,304
|
|
406
|
439
|
252
|
207
|
|
Actual change
|
|
14%
|
|
32%
|
6%
|
12%
|
2%
|
|
CER change
|
|
17%
|
|
33%
|
6%
|
21%
|
11%
|
|
Region
|
|
|
|
Worldwide
|
|
Increased
adjuvant and 1st-line use offset by a continued adverse COVID-19
impact on diagnosis, testing and treatment
|
|
Emerging Markets
|
|
Increased
1st-line use in China and continued growth in other Emerging
Markets
Tagrisso was admitted to the China NRDL in March 2021
for the 1st-line setting and renewed in the 2nd-line setting,
resulting in an adverse effect on the comparator period from lower
sales to distributors prior to the change and stock compensation
payments
Rising
demand from increased patient access in China has now offset the
impact of the March 2021 NRDL price reduction
|
|
US
|
|
Greater
1st-line and adjuvant use, with longer duration of treatment,
partially offset by lower 2nd-line use and a continued adverse
COVID-19 impact
At
the end of Q1 rates of diagnosis, testing and treatment in lung
cancer are showing some signs of recovery, but remained around
5-15% below baseline
|
|
Established RoW
|
|
Increased
use in 1st-line and adjuvant settings
|
Imfinzi
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
599
|
|
58
|
315
|
125
|
101
|
|
Actual change
|
|
8%
|
|
2%
|
8%
|
15%
|
4%
|
|
CER change
|
|
11%
|
|
3%
|
8%
|
23%
|
12%
|
|
Region
|
|
|
|
Worldwide
|
|
Increased use
of Imfinzi to
treat patients with ES-SCLC[45] was
offset by impact from lower rates of diagnosis and treatment due to
the current COVID-19 wave
|
|
Emerging Markets
|
|
Growth
in ex-China continued, offset in China by reduction in inventory
held by distributors and hospitals
|
|
US
|
|
Growth
driven new patient starts across Stage III NSCLC and ES-SCLC,
despite the impact of COVID-19 on lung cancer diagnoses in recent
months, offset by unfavourable seasonal inventory and gross-to-net
movements
|
|
Europe
|
|
ES-SCLC
market penetration increased, as did the number of reimbursed
markets, offsetting the COVID-19 impact on rates of diagnosis and
treatment
|
|
Established RoW
|
|
Growth
driven by new reimbursements
|
Lynparza
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
792
|
|
121
|
270
|
335
|
66
|
|
Actual change
|
|
46%
|
|
39%
|
7%
|
>2x
|
22%
|
|
CER change
|
|
50%
|
|
43%
|
7%
|
>2x
|
32%
|
|
Product Sales
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
617
|
|
121
|
270
|
160
|
66
|
|
Actual change
|
|
14%
|
|
39%
|
7%
|
8%
|
22%
|
|
CER change
|
|
17%
|
|
43%
|
7%
|
16%
|
32%
|
|
Region
|
|
|
|
Worldwide
|
|
Total
Revenue includes a $175m regulatory milestone received from MSD and
recognised in the Europe geographic segment, in respect of the
approval in the US for the adjuvant treatment of patients with
breast cancer, based on the data from the OlympiA Phase III
trial
Product sales growth was driven
by further launches across multiple cancer types
globally. Lynparza remains
the leading medicine in the PARP[46]-inhibitor
class globally across four tumour types, as measured by total
prescription volume
|
|
Emerging Markets
|
|
Patient access to Lynparza increased following admission to China's
NRDL as a 1st-line treatment for ovarian cancer patients with
effect from March 2021 and launches in other
markets
|
|
US
|
|
Growth
in use in ovarian, breast and prostate cancers, offset by an
adverse gross-to-net movement related to seasonal increase in
Part-D related deductions typically seen in the first quarter, and
reductions in inventory held by distributors
|
|
Europe
|
|
Reimbursements introduced in
additional countries, increasing BRCAm-testing rates, and
successful 1st-line BRCAm ovarian, 2nd-line HRRm[47] prostate
and gBRCAm HER2-negative advanced breast cancer
launches
|
|
Established RoW
|
|
Strong
year on year growth driven by new product launches and high levels
of HRD testing in Japan
|
Enhertu
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
86
|
|
9
|
57
|
20
|
1
|
|
Actual change
|
|
>2x
|
|
>7x
|
61%
|
>5x
|
n/m
|
|
CER change
|
|
>2x
|
|
>7x
|
61%
|
>5x
|
n/m
|
|
Region
|
|
|
|
Worldwide
|
|
Excluding
Japan, global in-market sales recorded by Daiichi Sankyo Company
Limited (Daiichi Sankyo) and AstraZeneca, amounted to $166m in the
quarter (Q1 2021: $81m)
|
|
US
|
|
US
in-market sales, recorded by Daiichi Sankyo, amounted to $119m in
the quarter (Q1 2021: $73m)
|
|
Established RoW
|
|
In
Japan, AstraZeneca receives a mid-single-digit percentage royalty
on sales made by Daiichi Sankyo
|
Calquence
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
414
|
|
7
|
339
|
55
|
13
|
|
Actual change
|
|
98%
|
|
>3x
|
74%
|
>5x
|
>4x
|
|
CER change
|
|
100%
|
|
>3x
|
74%
|
>6x
|
>4x
|
|
Region
|
|
|
|
US
|
|
Strong
performance despite COVID-19 impacts on CLL diagnosis rates,
benefitting from increased new patient market share
|
|
Europe
|
|
Increased
market share in new patient starts after launches in the
region
|
Orpathys
Total Revenue of $11m in the quarter (2021: $nil) was driven by the
2021 launch in China, where Orpathys has
been approved for patients with lung cancer and
MET[48] gene
alterations.
Other Oncology medicines
|
|
|
Q1 2022
|
% Change
|
|
||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
|
|
Zoladex
|
|
247
|
10
|
13
|
Increase
driven by usage in emerging markets
|
|
|
Faslodex
|
|
93
|
(24)
|
(20)
|
|
|
|
Iressa
|
|
32
|
(47)
|
(47)
|
|
|
|
Arimidex
|
|
32
|
(27)
|
(25)
|
|
|
|
Casodex
|
|
21
|
(48)
|
(47)
|
|
|
|
Others
|
|
12
|
1
|
6
|
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals
Including Vaccines & Immune Therapies medicines,
BioPharmaceuticals Total Revenue increased by 49% (53% at CER) in
Q1 2022 to $5,617m, representing 49% of overall Total Revenue (Q1
2021: 51%). Growth was driven by strong Farxiga performance and growth in the COVID-19
medicines.
Cardiovascular, Renal & Metabolism
CVRM Total Revenue increased by 14% (18% at CER) in Q1 2022, driven
by strong Farxiga performance, to $2,219m and represented 19%
of overall Total Revenue (Q1 2021: 26%).
Farxiga
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
1,001
|
|
391
|
193
|
318
|
99
|
|
Actual change
|
|
60%
|
|
50%
|
48%
|
83%
|
64%
|
|
CER change
|
|
67%
|
|
54%
|
48%
|
97%
|
76%
|
|
Region
|
|
|
|
Worldwide
|
|
The SGLT2[49] inhibitor
class saw growth in many regions, with Farxiga volume
growing faster than the overall SGLT2 market in most major regions.
Performance also reflecting further HF and CKD launches and updated
treatment guidelines including from ESC[50],
AHA[51] and
ACC[52],
and beneficial impact from gross-to-net adjustments in the US
versus Q1 2021
|
|
Emerging Markets
|
|
China performance was enhanced by
uACR[53] and
MRF[54] testing
program, and solid growth in ex-China Emerging
Markets. Forxiga's NRDL
status in China was renewed in the fourth quarter of
2021
|
|
US
|
|
Continued strong growth,
following the regulatory approval for HFrEF in May 2020, the
approval for the treatment of CKD in May 2021, and the
aforementioned gross-to-net adjustments. Both approvals included
patients with and without T2D[55]. Farxiga continued
to gain in-class brand share driven by HF and CKD
launches.
|
|
Europe
|
|
SGLT2
inhibitor class growth, the beneficial addition of cardiovascular
outcomes trial data to the label, the HFrEF regulatory approval in
November 2020, and CKD regulatory approval in August
2021
|
|
Established RoW
|
|
In
Japan, sales to collaborator Ono Pharmaceutical Co., Ltd, which
records in-market sales, more than doubled to $69m
|
Brilinta
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
325
|
|
69
|
166
|
76
|
14
|
|
Actual change
|
|
(13%)
|
|
(35%)
|
-
|
(13%)
|
(5%)
|
|
CER change
|
|
(10%)
|
|
(32%)
|
-
|
(6%)
|
(1%)
|
|
Region
|
|
|
|
Worldwide
|
|
Continued
adverse China VBP impact and fewer elective procedures in the EU
and US due to the effects of the pandemic
|
Lokelma
Total Revenue increased 92% (97% at CER) to $63m in the quarter,
driven by Lokelma extending its branded market share lead in
the US and continued progress from recent launches across Europe.
In China, Lokelma was included on the NRDL from 1 January
2022.
Andexxa
On a pro forma basis, Total Revenue increased 48% (49% at CER) to
$43m.
Roxadustat
Total Revenue increased 1% (2% decrease at CER) to $41m. Total
Revenue also increased sequentially, benefitting from increased
volumes in China following NRDL price cuts.
Other CVRM medicines
|
Total Revenue
|
|
Q1 2022
|
% Change
|
|
||
|
|
|
$m
|
Actual
|
CER
|
|
|
|
Crestor
|
|
268
|
(2)
|
-
|
Sales
decline in the US and Europe offset by growth in Emerging
Markets
|
|
|
Seloken/Toprol-XL
|
|
245
|
(2)
|
(1)
|
Emerging Markets sales impacted
by China VBP implementation of Betaloc[56] oral
in H2 2021. Betaloc ZOK VBP
to be implemented later in 2022
|
|
|
Bydureon
|
|
68
|
(34)
|
(33)
|
Continued
competitive pressures
|
|
|
Onglyza
|
|
68
|
(33)
|
(31)
|
Continued declines in
DPP-4[57] inhibitor
class
|
|
|
Others
|
|
98
|
(15)
|
(13)
|
|
|
|
|
|
|
|
|
|
|
Respiratory & Immunology
R&I Total Revenue, which included Collaboration Revenue of
$75m, increased by 2% in Q1 2022 (4% at CER) to $1,584m and
represented 14% of overall Total Revenue (Q1 2021: 21%). COVID-19
continued to have a material impact across markets and the
portfolio.
Symbicort
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
674
|
|
167
|
259
|
157
|
91
|
|
Actual change
|
|
(2%)
|
|
1%
|
(2%)
|
(7%)
|
(1%)
|
|
CER change
|
|
-
|
|
3%
|
(2%)
|
-
|
3%
|
|
Region
|
|
|
|
Worldwide
|
|
Symbicort remains the global market-volume and value
leader within the ICS/LABA class.
Market
share performance was driven by Established RoW and Emerging
Markets, and growth in anti-inflammatory reliever launch
markets
The
global ICS/LABA market continues to be eroded as fixed-dose triple
therapies (LAMA/LABA/ICS) continue to launch
|
|
Emerging Markets
|
|
Driven
by growth outside China. China continues to be impacted by
fixed-dose triple therapy launches
|
|
US
|
|
Maintained
total prescription market share in a declining ICS/LABA market as
fixed-dose triple therapy launches continue. Continued growth
in the authorised generic
|
|
Established RoW
|
|
Sales
in Japan declined due to continued generic erosion
|
Fasenra
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
308
|
|
7
|
189
|
75
|
37
|
|
Actual change
|
|
18%
|
|
>2x
|
22%
|
20%
|
(5%)
|
|
CER change
|
|
22%
|
|
>2x
|
22%
|
29%
|
2%
|
|
Region
|
|
|
|
Worldwide
|
|
Expanded total market leadership in eosinophilic
asthma, Fasenra is the leading IL-5 class biologic, in major
markets (US, Japan and some EU countries). COVID-19 continues to
impact total severe asthma market growth with most regions
experiencing a slower growth
|
|
US
|
|
Sustained
growth driven by volume
|
|
Europe
|
|
Increased
volume from sustained leadership in new to brand prescriptions, in
most EU markets
|
|
Established RoW
|
|
In
Japan, revenues declined by 13% (5% at CER) to $23m, with rising
demand and sustained leadership in new to brand prescriptions,
offset by reduced demand from distributors ahead of expected
mandatory price reduction in April
|
Breztri
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
87
|
|
22
|
53
|
5
|
7
|
|
Actual change
|
|
>3x
|
|
>2x
|
>4x
|
>7x
|
46%
|
|
CER change
|
|
>3x
|
|
>2x
|
>4x
|
>8x
|
59%
|
|
Region
|
|
|
|
Worldwide
|
|
Continued
to gain market share within the fixed-dose triple markets; in US,
China and Japan.
|
|
Emerging Markets
|
|
Continued
its market share leadership within the fixed-dose triple market in
China, which continues to gain share from the ICS/LABA
class
|
|
US
|
|
Progress
made in new to brand market share growth in the fixed-dose triple
market
|
|
Europe
|
|
Launches
continued in Europe
|
|
Established RoW
|
|
Sales
in Japan were impacted by COVID-19 restrictions
|
Saphnelo
Total Revenue of $11m in the quarter (Q1 2021: $nil) was driven by
the 2021 launch in the US, where Saphnelo has been approved for
SLE.
Tezspire
Tezspire is being
developed in collaboration with Amgen, and was approved in the US
for severe asthma in December 2021. Amgen will record sales in the
US and AstraZeneca's share of gross profits in the US will be
recognised as Collaboration Revenue. Outside of the US, AstraZeneca
will record Product Sales. In Q1 2022, AstraZeneca recognised $3m
of Collaboration Revenue from $7m of in-market sales recorded by
Amgen (Q1 2021: $nil).
Other R&I Medicines
|
|
|
Q1 2022
|
% Change
|
|
||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
|
Pulmicort
|
|
217
|
(34)
|
(34)
|
Revenue
from Emerging Markets decreased 43% to $164m
Pulmicort
Respules was included in
the latest round of VBP in China, implemented in October 2021,
resulted in significantly lower market access and a mandatory price
reduction.
|
|
|
Daliresp
|
|
51
|
(16)
|
(16)
|
|
|
|
Bevespi
|
|
15
|
15
|
14
|
|
|
|
Others
|
|
218
|
32
|
32
|
|
|
|
|
|
|
|
|
|
|
Vaccines & Immune Therapies
Total Revenue from Vaccines and Immune Therapies medicines
increased from $301m in Q1 2021 to $1,814m in Q1 2022 and
represented 16% of overall Total Revenue (Q1 2021:
4%).
Vaxzevria
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
1,145
|
|
530
|
79
|
135
|
400
|
|
Actual change
|
|
>4x
|
|
>10x
|
n/m
|
(40%)
|
>10x
|
|
CER change
|
|
>4x
|
|
>10x
|
n/m
|
(37%)
|
>10x
|
|
Region
|
|
|
|
Worldwide
|
|
The
majority of revenue in Q1 2022 came from initial, not-for-profit
contracts
|
|
Emerging Markets
|
|
Growth
was driven by initial and commercial contracts in Latin America and
Asia
$46m
of Collaboration Revenue came from a Chinese
sub-licensee
|
|
US
|
|
Purchases
by the US government for donation overseas
|
|
Europe
|
|
Sales were down versus Q1 2021, when Europe
accounted for 82% of Vaxzevria revenue as vaccination programmes were
rolled out in the UK and the EU
|
|
Established RoW
|
|
Sales
in Japan, Canada and Australia
|
Evusheld
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
469
|
|
89
|
307
|
66
|
8
|
|
Actual change
|
|
n/m
|
|
n/m
|
n/m
|
n/m
|
n/m
|
|
CER change
|
|
n/m
|
|
n/m
|
n/m
|
n/m
|
n/m
|
|
Region
|
|
|
|
US
|
|
Emergency
Use Authorisation was granted in December 2021, and in Q1
2022
AstraZeneca fulfilled a proportion of the US
government order for 1.7m units of Evusheld (a unit consists of one 150mg vial of
cilgavimab and one 150mg vial of tixagevimab). The remainder of
that order will be fulfilled before the end of
2022
|
|
Emerging Markets
|
|
Multiple
government contracts
|
|
Europe
|
|
Evusheld was approved in the EU in the
quarter
|
Other V&I Medicines
|
|
|
Q1 2022
|
% Change
|
|
||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
|
Synagis
|
|
200
|
>8x
|
>8x
|
Q1 2022 captures all global revenues
from Synagis by destination. In the comparable period,
revenues reflected AstraZeneca's ex-US collaboration agreement with
AbbVie, which expired on 30 June 2021 in which all ex-US revenue
was reported in Europe. The regional growth rates shown in Table 22
have also been impacted by the change
|
|
|
FluMist
|
|
(1)
|
n/m
|
n/m
|
Normal seasonality of FluMist sales
|
|
|
|
|
|
|
|
|
|
Rare Disease
Rare Disease Total Revenue increased by 3% (7% at CER) pro forma in
Q1 2022 to $1,694m, representing 15% of overall Total Revenue (Q1
2021: 0%). Performance was driven by continued durability of
the C5 franchise, including continued conversion
from Soliris to Ultomiris in PNH and aHUS as well
as Soliris growth in Neurology indications, gMG and
NMOSD.
The pro forma growth rates on medicines acquired with Alexion shown
in these tables have been calculated by comparing Q1 revenues with
the corresponding prior year pre-acquisition revenues previously
published by Alexion.
Soliris
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
990
|
|
71
|
591
|
221
|
107
|
|
Actual change
|
|
(5%)
|
|
(41%)
|
7%
|
(15%)
|
4%
|
|
CER change
|
|
-
|
|
(28%)
|
7%
|
(8%)
|
11%
|
|
Region
|
|
|
|
US
|
|
Performance driven by Soliris growth in neurology indications, gMG and
NMOSD, offset by continued conversion to Ultomiris in PNH and aHUS
|
|
Ex-US
|
|
Strong
underlying demand growth in EU and ERoW, EM growth impacted by
prior year tender market order timing
|
Ultomiris
|
Total Revenue
|
|
Worldwide
|
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|
Q1 2022 $m
|
|
419
|
|
24
|
220
|
105
|
70
|
|
Actual change
|
|
20%
|
|
n/m
|
6%
|
54%
|
(4%)
|
|
CER change
|
|
25%
|
|
n/m
|
6%
|
65%
|
7%
|
|
Region
|
|
|
|
Worldwide
|
|
Continued
conversion and launches in new markets outside the US
Quarter-on-quarter revenue growth variability can
be expected due to Ultomiris every eight-week dosing schedule and lower
average annual treatment cost per patient compared
to Soliris
|
|
US
|
|
Continued
COVID-19 impact on rate of aHUS diagnoses and treatment
coupled with hospital reimbursement dynamics favouring
Soliris
|
|
Ex-US
|
|
Performance
driven by new market approvals for PNH
|
Other Rare Disease medicines
|
|
|
Q1 2022
|
% Change
|
|
|||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
|
|
|
Strensiq
|
|
208
|
5
|
7
|
Performance
impacted by inventory and payer dynamics
|
|
|
|
Koselugo
|
|
39
|
82
|
85
|
Reimbursed
in 14 markets with ambition to continue expansion
|
|
|
|
Kanuma
|
|
38
|
9
|
15
|
Performance
driven by markets outside the US
|
|
|
|
|
|
|
|
|
|
|
|
Other medicines (outside the main disease areas)
|
|
|
Q1 2022
|
% Change
|
|
|||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
|
|
|
Nexium
|
|
338
|
(17)
|
(13)
|
Nexium
(oral) was included in China's VBP programme implemented in
February 2021 and Nexium (i.v.) was implemented in the fifth round
of VBP in October 2021.
|
|
|
|
Others
|
|
97
|
(22)
|
(21)
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial performance
Table 8: Reported Profit and Loss
|
|
|
Q1 2022
|
Q1 2021
|
%
Change
|
||
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Total Revenue
|
|
11,390
|
7,320
|
56
|
60
|
|
|
- Product Sales
|
|
10,980
|
7,257
|
51
|
56
|
|
|
- Collaboration Revenue
|
|
410
|
63
|
n/m
|
n/m
|
|
|
Cost of Sales
|
|
(3,511)
|
(1,864)
|
88
|
98
|
|
|
Gross Profit
|
|
7,879
|
5,456
|
44
|
48
|
|
|
Gross Margin
|
|
68.0%
|
74.3%
|
-6
|
-7
|
|
|
Distribution Expense
|
|
(125)
|
(99)
|
26
|
32
|
|
|
% Total Revenue
|
|
1.1%
|
1.4%
|
-
|
-
|
|
|
R&D Expense
|
|
(2,133)
|
(1,713)
|
24
|
26
|
|
|
% Total Revenue
|
|
18.7%
|
23.4%
|
+5
|
+5
|
|
|
SG&A Expense
|
|
(4,840)
|
(2,929)
|
65
|
68
|
|
|
% Total Revenue
|
|
42.5%
|
40.0%
|
-2
|
-2
|
|
|
OOI[58] &
Expense
|
|
97
|
1,180
|
(92)
|
(92)
|
|
|
% Total Revenue
|
|
0.9%
|
16.1%
|
-15
|
-15
|
|
|
Operating Profit
|
|
878
|
1,895
|
(54)
|
(46)
|
|
|
Operating Margin
|
|
7.7%
|
25.9%
|
-18
|
-18
|
|
|
Net Finance Expense
|
|
(319)
|
(283)
|
13
|
7
|
|
|
Joint Ventures and Associates
|
|
(6)
|
(4)
|
38
|
53
|
|
|
Profit before tax
|
|
553
|
1,608
|
(66)
|
(56)
|
|
|
Taxation
|
|
(165)
|
(46)
|
n/m
|
n/m
|
|
|
Tax rate
|
|
30%
|
3%
|
|
|
|
|
Profit after tax
|
|
388
|
1,562
|
(75)
|
(68)
|
|
|
Earnings per share
|
|
$0.25
|
$1.19
|
(79)
|
(73)
|
|
Table 9: Reconciliation of Reported Profit before tax to
EBITDA
|
|
|
Q1 2022
|
Q1 2021
|
%
Change
|
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit before tax
|
|
553
|
1,608
|
(66)
|
(56)
|
|
Net Finance Expense
|
|
319
|
283
|
13
|
7
|
|
Joint Venture and Associates
|
|
6
|
4
|
38
|
53
|
|
Depreciation, Amortisation and Impairment
|
|
1,309
|
797
|
64
|
56
|
|
EBITDA
|
|
2,187
|
2,692
|
(19)
|
(16)
|
EBITDA of $2,187m in the quarter (Q1 2021: $2,692m) has been
negatively impacted by the $1,180m (Q1 2021: $nil) unwind of
inventory fair value uplift recognised on the acquisition of
Alexion. The unwind of inventory fair value is expected to depress
EBITDA over the year in line with associated revenues.
Table 10: Reconciliation of Reported to Core financial
measures
|
Q1 2022
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion
|
Other
|
Core[59]
|
Core
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
7,879
|
51
|
8
|
1,181
|
-
|
9,119
|
66
|
70
|
|
Gross Margin
|
68.0%
|
|
|
|
|
79.3%
|
+5
|
+4
|
|
Distribution Expense
|
(125)
|
1
|
-
|
-
|
-
|
(124)
|
25
|
30
|
|
R&D Expense
|
(2,133)
|
5
|
(69)
|
11
|
-
|
(2,186)
|
33
|
36
|
|
SG&A Expense
|
(4,840)
|
17
|
1,098
|
17
|
762
|
(2,946)
|
23
|
25
|
|
Total Operating Expense
|
(7,098)
|
23
|
1,029
|
28
|
762
|
(5,256)
|
27
|
29
|
|
OOI & Expense
|
97
|
1
|
-
|
-
|
-
|
98
|
(92)
|
(92)
|
|
Operating Profit
|
878
|
75
|
1,037
|
1,209
|
762
|
3,961
|
57
|
60
|
|
Operating Margin
|
7.7%
|
|
|
|
|
34.8%
|
-
|
-
|
|
Net Finance Expense
|
(319)
|
-
|
-
|
-
|
67
|
(252)
|
35
|
23
|
|
Taxation
|
(165)
|
(15)
|
(191)
|
(280)
|
(121)
|
(772)
|
n/m
|
n/m
|
|
EPS
|
$0.25
|
$0.04
|
$0.55
|
$0.60
|
$0.45
|
$1.89
|
16
|
20
|
Profit and Loss drivers
Gross Profit
‒ The
Gross Profit Margin (Reported and Core) in the quarter was impacted
by:
‒ Mix
effects. The increased sales of Vaxzevria, and medicines with profit-sharing
arrangements (primarily Lynparza) have a dilutive impact on the Gross Margin. The
increased contribution from Rare Disease and Oncology medicines
have a positive impact on the Gross Margin
‒ Pricing
pressure relating to the VBP and NRDL procurement programmes in
China
‒ Reported
Gross Profit was also impacted by the unwind of the fair value
adjustment to Alexion inventories at the date of acquisition. The
fair value uplift is expected to unwind through Reported Cost of
Sales over 2022 in line with associated revenues, and in Q1 2022,
the impact of the fair value uplift unwind on Cost of Sales was
$1,180m
‒ Variations
in Gross Margin performance between periods can be expected to
continue
R&D Expense
‒ The
increased Reported and Core R&D Expense was driven
by:
‒ Increased
investment in several late-stage Oncology trials and the
advancement of a number of Phase II clinical development
programmes in BioPharmaceuticals
‒ The
acquisition of Alexion in July 2021
‒ Reported
R&D Expense in Q1 was also impacted by intangible asset
impairment reversals
SG&A Expense
‒ The
increased Reported and Core SG&A Expense was driven primarily
by the acquisition of Alexion in July 2021
‒ Reported
SG&A Expense was also impacted by amortisation of intangible
assets related to the Alexion acquisition and a $775m legal
settlement with Chugai Pharmaceutical Co. Ltd
Other Operating Income
‒ Other
Operating Income of $97m consisted primarily of royalties and
disposal proceeds on small divestments
‒ In
Q1 2021, Other Operating Income of $1,180m included $776m of
divestment gains from AstraZeneca's share of Viela and $309m from
the commercial rights to Crestor in over 30 countries in Europe
(excluding UK and Spain)
Net Finance Expense
‒ The
increase in Net Finance Expense in the quarter was driven by
financing costs on debt for the Alexion transaction, increased
interest on tax, and exchange movements
Taxation
‒ Both
Reported and Core Tax rates are higher than the prior period due to
one-off items in 2021, including the non-taxable gain on the
divestment of Viela and updates to estimates of prior period tax
liabilities following settlements with tax
authorities
‒ The
net cash paid for the quarter was $228m (Q1 2021: $332m)
representing 41% of Reported Profit Before Tax (Q1 2021:
21%)
‒ The
Reported Tax rate of 30% was higher than Core Tax rate of 21% due
to the impact of Non-Core charges on the level of Reported Profit
Before Tax
Table 11: Cash Flow summary
|
|
|
Q1 2022
|
Q1 2021
|
Change
|
|
|
|
$m
|
$m
|
$m
|
|
Reported Operating Profit
|
|
878
|
1,895
|
(1,017)
|
|
Depreciation, Amortisation and Impairment
|
|
1,309
|
797
|
512
|
|
Decrease in Working Capital and Short-term Provisions
|
|
1,804
|
1,210
|
594
|
|
Gains on Disposal of Intangible Assets
|
|
(10)
|
(310)
|
300
|
|
Gains on Disposal of Investments in Associates and Joint
Ventures
|
|
-
|
(776)
|
776
|
|
Non-Cash and Other Movements
|
|
(327)
|
(363)
|
36
|
|
Interest Paid
|
|
(194)
|
(187)
|
(7)
|
|
Taxation Paid
|
|
(228)
|
(332)
|
104
|
|
Net Cash Inflow from Operating Activities
|
|
3,232
|
1,934
|
1,298
|
|
Net Cash Inflow before Financing Activities
|
|
3,064
|
2,489
|
575
|
|
Net Cash Outflow from Financing Activities
|
|
(3,740)
|
(2,731)
|
(1,009)
|
The increase in Net Cash Inflow from Operating Activities of
$1,298m primarily reflected an underlying improvement in business
performance, including the contribution from Alexion.
The Reported Operating Profit of $878m in the quarter includes a
negative impact of $1,180m relating to the unwind of the inventory
fair value uplift recognised on the acquisition of Alexion. This is
offset by a corresponding item (positive impact of $1,180m) in
Decrease in Working Capital and Short-term Provisions. Overall, the
unwind of the fair value uplift has no impact on Net Cash Inflow
from Operating Activities.
The change in Working Capital and Short-term Provisions of $594m,
whilst being positively impacted by the aforementioned inventory
fair value uplift unwind, has been adversely impacted by the
reduction of Vaxzevria working capital balances predominantly
within Trade and other payables.
Capital Expenditure
Capital Expenditure amounted to $219m in the quarter (Q1 2021:
$220m). The Company anticipates an increase in Capital Expenditure
relative to FY 2021, partly driven by an expansion in its capacity
for growth and the acquisition of Alexion.
Table 12: Net Debt summary
|
|
|
At 31 Mar 2022
|
At 31 Dec 2021
|
At 31 Mar 2021
|
|
|
|
$m
|
$m
|
$m
|
|
Cash and cash equivalents
|
|
5,762
|
6,329
|
7,636
|
|
Other investments
|
|
61
|
69
|
129
|
|
Cash and investments
|
|
5,823
|
6,398
|
7,765
|
|
Overdrafts and short-term borrowings
|
|
(805)
|
(387)
|
(581)
|
|
Lease liabilities
|
|
(949)
|
(987)
|
(680)
|
|
Current instalments of loans
|
|
(1,264)
|
(1,273)
|
(1,461)
|
|
Non-current instalments of loans
|
|
(28,081)
|
(28,134)
|
(17,410)
|
|
Interest-bearing loans and borrowings
(Gross Debt)
|
|
(31,099)
|
(30,781)
|
(20,132)
|
|
Net derivatives
|
|
59
|
61
|
162
|
|
Net Debt
|
|
(25,217)
|
(24,322)
|
(12,205)
|
Net Debt increased by $895m in the year to date to $25,217m.
Details of the committed undrawn bank facilities are disclosed
within the going concern section of Note 1. Details of the
Company's solicited credit ratings are disclosed in Note
3.
Capital allocation
The Board's aim is to continue to strike a balance between the
interests of the business, financial creditors and the Company's
shareholders. The Company's capital allocation priorities include
investing in the business and pipeline, maintaining a strong,
investment-grade credit rating, potential value-enhancing business
development opportunities, and supporting the progressive dividend
policy.
In approving the declaration of dividends, the Board considers both
the liquidity of the company and the level of reserves legally
available for distribution. Dividends are paid to shareholders from
AstraZeneca PLC, a Group holding company with no direct operations.
The ability of AstraZeneca PLC to make shareholder distributions is
dependent on the creation of profits for distribution and the
receipt of funds from subsidiary companies. The consolidated Group
reserves set out in the Condensed consolidated statement of
financial position do not reflect the profit available for
distribution to the shareholders of AstraZeneca PLC.
Summarised financial information for guarantee of securities of
subsidiaries
AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of
0.700% Notes due 2024, 1.200% Notes due 2026, 1.750% Notes due 2028
and 2.250% Notes due 2031 (the "AstraZeneca Finance Notes"). Each
series of AstraZeneca Finance Notes has been fully and
unconditionally guaranteed by AstraZeneca PLC. AstraZeneca Finance
is 100% owned by AstraZeneca PLC and each of the guarantees by
AstraZeneca PLC is full and unconditional and joint and
several.
The AstraZeneca Finance Notes are senior unsecured obligations of
AstraZeneca Finance and rank equally with all of AstraZeneca
Finance's existing and future senior unsecured and unsubordinated
indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca
Finance Notes is the senior unsecured obligation of AstraZeneca PLC
and ranks equally with all of AstraZeneca PLC's existing and future
senior unsecured and unsubordinated indebtedness. Each guarantee by
AstraZeneca PLC is effectively subordinated to any secured
indebtedness of AstraZeneca PLC to the extent of the value of the
assets securing such indebtedness. The AstraZeneca Finance Notes
are structurally subordinated to indebtedness and other liabilities
of the subsidiaries of AstraZeneca PLC, none of which guarantee the
AstraZeneca Finance Notes.
AstraZeneca PLC manages substantially all of its operations through
divisions, branches and/or investments in subsidiaries and
affiliates. Accordingly, the ability of AstraZeneca PLC to service
its debt and guarantee obligations is also dependent upon the
earnings of its subsidiaries, affiliates, branches and divisions,
whether by dividends, distributions, loans or
otherwise.
Please refer to the consolidated financial statements of
AstraZeneca PLC in our Annual Report on Form 20-F and reports on
Form 6-K with our quarterly financial results as filed or furnished
with the SEC for further financial information regarding
AstraZeneca PLC and its consolidated subsidiaries. For further
details, terms and conditions of the AstraZeneca Finance Notes
please refer to AstraZeneca PLC's Form 6-K furnished to the SEC on
28 May 2021.
Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the
Securities Act of 1933, as amended (the "Securities Act"), we
present below the summary financial information for AstraZeneca
PLC, as Guarantor, excluding its consolidated subsidiaries, and
AstraZeneca Finance, as the issuer, excluding its consolidated
subsidiaries. The following summary financial information of
AstraZeneca PLC and AstraZeneca Finance is presented on a combined
basis and transactions between the combining entities have been
eliminated. Financial information for non-guarantor entities has
been excluded. Intercompany balances and transactions between the
obligor group and the non-obligor subsidiaries are presented on
separate lines.
Table 13: Obligor group summarised Statement of comprehensive
income
|
|
|
Q1 2022
|
Q1 2021
|
|
|
|
$m
|
$m
|
|
Total revenue
|
|
-
|
-
|
|
Gross profit
|
|
-
|
-
|
|
Operating loss
|
|
(1)
|
(20)
|
|
Loss for the period
|
|
(155)
|
(166)
|
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
164
|
2,148
|
Table 14: Obligor group summarised Statement of financial
position information
|
|
|
At 31 Mar 2022
|
At 31 Mar 2021
|
|
|
|
$m
|
$m
|
|
Current assets
|
|
19
|
28
|
|
Non-current assets
|
|
-
|
-
|
|
Current liabilities
|
|
(1,682)
|
(1,656)
|
|
Non-current liabilities
|
|
(25,605)
|
(17,072)
|
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
8,652
|
6,243
|
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
(297)
|
(295)
|
Foreign exchange
The Company's transactional currency exposures on working-capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign-exchange contracts against
the individual companies' reporting currency. Foreign-exchange
gains and losses on forward contracts for transactional hedging are
taken to profit or loss. In addition, the Company's external
dividend payments, paid principally in pounds sterling and Swedish
krona, are fully hedged from announcement to payment
date.
Table 15: Currency sensitivities
The Company provides the following currency-sensitivity
information:
|
|
|
|
Average exchange
rates versus USD
|
|
Annual impact of 5%
strengthening in exchange rate versus USD ($m)[60]
|
|
Currency
|
Primary Relevance
|
|
FY 2021[61]
|
Q1 2022[62]
|
% Change
|
Total Revenue
|
Core Operating Profit
|
|
CNY
|
Total Revenue
|
|
6.43
|
6.35
|
1
|
277
|
158
|
|
EUR
|
Total Revenue
|
|
0.85
|
0.89
|
(5)
|
317
|
160
|
|
JPY
|
Total Revenue
|
|
109.83
|
116.32
|
(6)
|
229
|
158
|
|
Other[63]
|
|
|
|
|
|
420
|
196
|
|
GBP
|
Operating Expense
|
|
0.73
|
0.75
|
(2)
|
61
|
(93)
|
|
SEK
|
Operating Expense
|
|
8.58
|
9.33
|
(8)
|
6
|
(82)
|
Sustainability
Since the last quarterly report, AstraZeneca:
‒ Published
its eighth annual Sustainability
Report and Sustainability Data
summary via its website
and social media, released in conjunction with the Annual Report.
Two fireside discussions from the accompanying investor roadshow
are available on the AstraZeneca IR website
‒ Facilitated
a Climate and Health Policy Roundtable at Expo 2020 Dubai with
global experts from the World Health Organisation, UNFCCC,
Sustainability Healthcare Coalition, and health and environmental
authorities from Sweden, Egypt, and the UAE to discuss the health
of people and the planet
‒ Convened
a hybrid summit on health system sustainability and resilience,
culminating in a global call to action to rebuild health system
integrity following the COVID-19 pandemic
Access to healthcare
‒ Released,
along with its sub-licensees, more than 2.8 billion vaccine doses,
for supply in over 180 countries. Approximately two-thirds of the
doses have gone to low and middle-income
countries
‒ The
Company's Healthy Heart Africa (HHA) programme expanded into
Nigeria, its ninth country of operation, with the signing of a
Memorandum of Understanding with the Federal Government of Nigeria.
Launched the second phase in Tanzania with the Ministry of Health
and our local partner PATH. The two-year project aims to reach over
500,000 people, providing services and support at 35 primary health
care facilities. Since the programme launched in 2015, HHA has
conducted over 25 million blood pressure screenings, identified
over 4.8 million elevated readings, activated over 950 sites and
trained more than 9,000 healthcare workers and
volunteers
‒ Expanded
its Young Health Programme (YHP) into Italy and Israel, bringing
the number of countries to 34
‒ Awards
to two youth-led organisations tackling air pollution, through
the Lead2030 Challenge in
partnership with One Young World (OYW), in line with the Company's commitment to
SDG3. Winners receive mentorship from AstraZeneca, and a
Scholarship to attend the OYW Summit
Environmental protection
‒ Announced
a collaboration with
Honeywell to develop
next-generation respiratory inhalers (pMDI) with a near-zero Global
Warming Potential propellant. The innovation, using the propellant
HFO-1234ze, is a key element supporting the delivery of
AstraZeneca's Ambition Zero Carbon goals. AstraZeneca also
announced that by the end of 2025, 95% of its key suppliers will
have targets to limit global warming to
<1.5C
‒ Announced
two new forestry
commitments in Ghana (three million trees) and the
US (one million trees) at
the Global Forest Summit, building on existing AZ Forest projects
in Australia, Indonesia, the UK
‒ Marked
World Water Day with an updated Position Paper
on Water
Stewardship. The Company has
championed a water risk assessment of the global pharmaceutical
supply chain in collaboration with WWF Sweden. AstraZeneca also
joined the Alliance for Water Stewardship (AWS)
‒ Featured
in the Financial Times' list of Europe's Climate
Leaders, for the second year
running. This recognises companies with the highest reduction
in Scope 1 and 2 emissions from 2015 to
2020
Ethics and transparency
‒ Revised
its Global Standard for
Bioethics, which ensures its
ethical principles cover evolving R&D
activities
‒ Marked
International Day of Women and Girls in Science and International
Women's Day with external and internal communications campaigns
featuring members of the Senior Executive team and other Company
scientists. AstraZeneca also signed the Wellbeing of
Women Menopause Workplace
Pledge
‒ Observed
Black History Month, with events hosted by the AstraZeneca African
Heritage Business Resource Group, Alexion Black Professionals
Network, AZ Inspire and the Inclusion and Diversity (I&D)
team
‒ Became
a founding member of Neurodiversity in Business and celebrated
Neurodiversity Week with the Company's TH!NK ERG programme of
events
Research and development
This section covers R&D events and milestones in the period
since the prior results announcement.
A comprehensive view of AstraZeneca's pipeline of medicines in
human trials can be found in the latest clinical trials appendix,
available on www.astrazeneca.com/investor-relations.
The clinical trials appendix includes tables with details of the
ongoing clinical trials for AstraZeneca medicines and new molecular
entities in the pipeline.
Oncology
Significant new trials in Oncology included, EMERALD-3, a Phase III
trial of Imfinzi plus tremelimumab, with and without
lenvatinib, in combination with transarterial chemoembolisation in
patients with locoregional HCC, PACIFIC-9, a Phase III trial
of Imfinzi plus oleclumab and Imfinzi plus monalizumab in patients with locally
advanced, Stage III, unresectable non-small cell lung cancer who
have not progressed following platinum-based cCRT, and SAFFRON - a
Phase III trial of Tagrisso in combination with AstraZeneca and
HUTCHMED's Orpathys in patients EGFR-mutated NSCLC patients with
MET-driven tumours following progression after treatment
with Tagrisso.
AstraZeneca presented new data across its diverse portfolio of
cancer medicines at the American Society of Clinical Oncology
Genitourinary Cancers Symposium (ASCO GU) in February 2022.
Presentations included a late-breaking presentation by AstraZeneca
and MSD from the PROpel Phase III trial of Lynparza plus abiraterone, which showed the
combination significantly delayed disease progression in 1st-line
metastatic castration-resistant prostate cancer regardless of
biomarker status. Lynparza is the first PARP inhibitor to demonstrate
clinical benefit in combination with a new hormonal agent in this
setting.
At the American Association for Cancer Research General Meeting
2022, new preclinical and early clinical data was presented across
its pipeline. Data from 60 presentations, including five oral and
three mini-oral presentations, featured the Company's next wave of
potential cancer medicines spanning its immuno-oncology, DNA Damage
Response and Antibody Drug Conjugate scientific platforms. This
includes key data shared from three potential new medicines that
illustrate the Company's innovative approach to designing molecules
that address key challenges in treating cancer, including the
ability to target different, complementary mechanisms.
Imfinzi
During the period, the Company announced that the CALLA Phase III
trial for Imfinzi given concurrently with CRT did not achieve
statistical significance for the primary endpoint of improving
progression-free survival versus CRT alone in the treatment of
patients with locally advanced cervical cancer.
In April 2022 the Company announced the regulatory submission
acceptance for tremelimumab with Priority Review in the US, by the
US FDA. The submission is supported by data from the HIMALAYA
trial, in which a single priming dose of the
anti-CTLA4[64] antibody
added to Imfinzi for the treatment of patients with
unresectable hepatocellular carcinoma significantly improved
overall survival. A supplemental Biologics Licence Application has
also been submitted for Imfinzi in this indication. The Prescription Drug
User Fee Act date, the US FDA action date for their regulatory
decision, is during the fourth quarter of 2022, following the use
of a priority review voucher.
During the period, AstraZeneca completed regulatory submissions for
tremelimumab and Imfinzi in Japan. The submissions were based on data
from the aforementioned HIMALAYA trial, as well as the TOPAZ-1
trial in which Imfinzi, in combination with standard-of-care
chemotherapy, demonstrated a statistically significant and
clinically meaningful overall survival benefit versus chemotherapy
alone as a 1st-line treatment for patients with advanced biliary
tract cancer.
Lynparza
In February 2022, AstraZeneca presented results from the PROpel
Phase III trial at the aforementioned 2022 ASCO GU meeting.
AstraZeneca and MSD's Lynparza in combination with abiraterone demonstrated
a statistically significant and clinically meaningful improvement
in rPFS[65] versus
abiraterone as a 1st-line treatment for patients with
mCRPC[66] with
or without HRR[67] gene
mutations.
Lynparza in combination
with abiraterone reduced the risk of disease progression or death
by 34% versus abiraterone alone (HR[68] 0.66;
95% CI 0.54-0.81; p<0.0001). Median rPFS was 24.8 months
for Lynparza plus abiraterone versus 16.6 for abiraterone
alone.
Results also showed a favourable trend towards improved
OS[69] with Lynparza plus
abiraterone versus abiraterone alone, however the difference did
not reach statistical significance at the time of this data cut-off
(analysis at 29% data maturity). The trial will continue to assess
OS as a key secondary endpoint.
During the period, Lynparza was also approved in the US for the adjuvant
treatment of patients with germline BRCA-mutated HER2-negative
high-risk early breast cancer who have already been treated with
chemotherapy either before or after surgery. The approval by the US
FDA was based on results from the OlympiA Phase III trial, in
which Lynparza demonstrated a statistically significant and
clinically meaningful improvement in invasive disease-free
survival, reducing the risk of invasive breast cancer recurrences,
second cancers or death, by 42% versus placebo (based on a HR of
0.58; 95% CI 0.46-0.74; p<0.0001).
In March, new updated results from the OlympiA trial presented at
the European Society for Medical Oncology virtual plenary
showed Lynparza demonstrated a statistically significant and
clinically meaningful improvement in the key secondary endpoint of
OS, reducing the risk of death by 32% versus placebo (based on a HR
of 0.68; 95% CI 0.50-0.91; p=0.0091).
Enhertu
In February 2022, AstraZeneca announced positive high-level results
from the DESTINY-Breast04 Phase III trial. Enhertu demonstrated a statistically significant and
clinically meaningful improvement in both PFS[70] and
OS in patients with HER2-low unresectable and/or metastatic breast
cancer previously treated with one or two prior lines of
chemotherapy, regardless of hormone receptor (HR) status, versus
physician's choice of chemotherapy.
The US FDA has subsequently notified AstraZeneca and Daiichi Sankyo
that the sBLA[71] for Enhertu has
been accepted and granted Breakthrough Therapy Designation for the
treatment of HER2-low unresectable and/or metastatic breast
cancer in patients previously treated with one or two prior lines
of chemotherapy.
The sBLA is being reviewed under the Real-Time Oncology Review
(RTOR) programme. RTOR allows the FDA to review components of an
application before submission of the complete
application.
In April 2022, AstraZeneca and Daiichi Sankyo were notified by the
US FDA that the sBLA for Enhertu has been accepted and granted Priority
Review for the treatment of adult patients with previously treated
HER2-mutant metastatic non-small cell lung cancer based on the
results of the DESTINY-Lung01 Phase II trial.
Primary results from previously-treated patients with
HER2-mutations (cohort 2) of DESTINY-Lung01 demonstrated a
confirmed objective response rate (ORR) of 54.9% (95% CI:
44.2-65.4) in patients treated with Enhertu (6.4mg/kg).
During the period, the China Center for Drug Evaluation granted
Breakthrough Therapy Designation for Enhertu for the 2nd-line treatment of patients with
HER2+ metastatic breast cancer based on the results of the
DESTINY-Breast03 Phase III trial.
BioPharmaceuticals - CVRM
Brilinta
During the period, the US FDA granted AstraZeneca six months
paediatric exclusivity for Brilinta.
Andexxa
During the period, Ondexxya was approved in Japan for patients treated
with Factor Xa inhibitors apixaban, rivaroxaban or edoxaban when
reversal of anticoagulation is needed due to life-threatening or
uncontrolled bleedings. Ondexxya is approved in the EU, and in the US under
the trade name Andexxa.
AZD8233
At the American College of Cardiology's 71st Annual Scientific
Session, AstraZeneca and Ionis Pharmaceuticals, Inc. presented
Phase IIb data for AZD8233, an antisense oligonucleotide, in
development for the treatment of hypercholesterolemia. In the
ETESIAN Phase IIb trial, AZD8233 showed reduction in
LDL-C[72] levels
of 73% and PCSK9 reduction of 89%.
BioPharmaceuticals Ð R&I
As disclosed in the Sustainability section, AstraZeneca announced a
collaboration with Honeywell, to develop next-generation
respiratory inhalers (pMDI) using the propellant HFO-1234ze, which
has up to 99.9% less Global Warming Potential (GWP) than
propellants currently used in respiratory medicines. Recent results
from the first in-human Phase I trial of the near-zero GWP
propellant HFO-1234ze in a pMDI containing budesonide,
glycopyrronium, formoterol fumarate in healthy adults were
positive, demonstrating similar safety, tolerability and systemic
exposure of the active ingredients when compared
to Breztri
Aerosphere (budesonide/glycopyrronium/formoterol
fumarate). AstraZeneca expects Breztri to be the first medicine to transition to
this new pMDI platform, subject to regulatory
approval.
As of 29 April 2022, significant new trials in Respiratory &
Immunology in which the first patient was dosed included; HUDSON, a
Phase III trial of Fasenra in eosinophilic gastritis and eosinophilic
gastroenteritis and, OBERON and TITANIA, Phase III trials of
tozorakimab in COPD.
Fasenra
During the period, the US FDA issued a CRL[73] regarding
the sBLA for Fasenra for patients with inadequately controlled
CRwNP
The sBLA included data from the OSTRO Phase III trial, which met
both co-primary endpoints with a safety profile consistent with the
known profile of the medicine. The CRL requested additional
clinical data and AstraZeneca is working closely with the US FDA
regarding next steps. AstraZeneca remains committed to
bringing Fasenra to patients with CRSwNP and a second Phase
III trial, ORCHID, in this indication is
ongoing.
Saphnelo
During the period, Saphnelo received approval in the EU as an add-on
therapy for the treatment of adult patients with moderate to
severe, active autoantibody-positive SLE, despite receiving
standard therapy, making it the first biologic for SLE approved in
Europe with an indication that is not restricted to patients with a
high degree of disease activity. The approval is based on results
from the Saphnelo clinical development programme, which
included the TULIP 1 and TULIP 2 Phase III trials and the MUSE
Phase II trial. In these trials, more patients treated
with Saphnelo experienced a reduction in overall disease
activity across all affected organ systems from baseline and
achieved sustained reduction in oral corticosteroid use compared to
placebo, with both groups receiving standard therapy.
BioPharmaceuticals Ð Vaccines and Immune
Therapies
Evusheld
During the period, Evusheld was granted marketing authorisation in the
EU for the pre-exposure prophylaxis (prevention) of COVID-19 in a
broad population of adults and adolescents aged 12 years and older
weighing at least 40kg.
Preclinical authentic Ôlive' virus data from Washington
University School of Medicine demonstrated
that Evusheld retains neutralising activity against the
highly transmissible Omicron BA.2 subvariant. This study also
showed that Evusheld reduced viral burden and limited
inflammation in the lungs (in vivo) across all tested Omicron
variants.
Detailed results from the PROVENT Phase III pre-exposure
prophylaxis (prevention) trial, published
in The New England Journal of
Medicine, showed that
AstraZeneca's Evusheld reduced the risk of developing symptomatic
COVID-19 by 77% in the primary analysis and by 83% in the six-month
follow-up analysis, compared to placebo. There were no cases of
severe disease or COVID-19 related deaths in
the Evusheld group through the six-month follow
up.
Nirsevimab
Nirsevimab was accepted under an accelerated assessment procedure
by the EMA, for the prevention of medically attended
LRTI[74] in
all infants from birth entering their first RSV
season.
Detailed results from the MELODY Phase III trial were published in
the New England Journal of Medicine and demonstrated that
nirsevimab showed 74.5% efficacy against medically attended LRTI
caused by RSV in healthy infants compared to placebo. Additionally,
results from the MEDLEY Phase II/III trial were also published in
the journal. The results demonstrated nirsevimab had a similar
safety and tolerability profile compared
to Synagis,
and that serum levels of nirsevimab following dosing (on day 151)
in this trial were comparable with those observed in the MELODY
Phase III trial.
Rare Disease
Ultomiris
Ultomiris was approved in
the US for the treatment of adult patients with gMG who are
anti-acetylcholine receptor antibody-positive, which represents 80%
of people living with the disease. The approval by the US FDA was
based on positive results from the CHAMPION-MG Phase III trial, in
which Ultomiris was superior to placebo in the primary
endpoint of change from baseline in the Myasthenia
Gravis-Activities of Daily Living Profile (MG-ADL) total score at
Week 26, a patient-reported scale that assesses patients' abilities
to perform daily activities.
Interim Financial Statements
Table 16: Q1 2022 - Condensed consolidated statement of
comprehensive income
|
For the quarter ended 31 March
|
2022
|
2021
|
|
$m
|
$m
|
|
Total Revenue
|
11,390
|
7,320
|
|
Product Sales
|
10,980
|
7,257
|
|
Collaboration Revenue
|
410
|
63
|
|
Cost of Sales
|
(3,511)
|
(1,864)
|
|
Gross profit
|
7,879
|
5,456
|
|
Distribution expense
|
(125)
|
(99)
|
|
Research and development expense
|
(2,133)
|
(1,713)
|
|
Selling, general and administrative expense
|
(4,840)
|
(2,929)
|
|
Other operating income and expense
|
97
|
1,180
|
|
Operating profit
|
878
|
1,895
|
|
Finance income
|
17
|
20
|
|
Finance expense
|
(336)
|
(303)
|
|
Share of after tax losses in associates and joint
ventures
|
(6)
|
(4)
|
|
Profit before tax
|
553
|
1,608
|
|
Taxation
|
(165)
|
(46)
|
|
Profit for the period
|
388
|
1,562
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
Remeasurement of the defined benefit pension liability
|
335
|
481
|
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
18
|
(108)
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
-
|
1
|
|
Tax on items that will not be reclassified to profit or
loss
|
(94)
|
(94)
|
|
|
259
|
280
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
Foreign exchange arising on consolidation
|
(219)
|
(107)
|
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
(32)
|
(302)
|
|
Fair value movements on cash flow hedges
|
5
|
(86)
|
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
11
|
121
|
|
Fair value movements on derivatives designated in net investment
hedges
|
(8)
|
13
|
|
Costs of hedging
|
-
|
(1)
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
1
|
26
|
|
|
(242)
|
(336)
|
|
Other comprehensive income/(loss) for the period, net of
tax
|
17
|
(56)
|
|
Total comprehensive income for the period
|
405
|
1,506
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners of the Parent
|
386
|
1,561
|
|
Non-controlling interests
|
2
|
1
|
|
|
388
|
1,562
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners of the Parent
|
405
|
1,506
|
|
Non-controlling interests
|
-
|
-
|
|
|
405
|
1,506
|
|
Basic earnings per $0.25 Ordinary Share
|
$0.25
|
$1.19
|
|
Diluted earnings per $0.25 Ordinary Share
|
$0.25
|
$1.18
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,548
|
1,312
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,561
|
1,319
|
Table 17: Condensed consolidated statement of financial
position
|
|
At 31 Mar 2022
|
At 31 Dec 2021
|
At 31 Mar 2021
|
|
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property, plant and equipment
|
9,061
|
9,183
|
8,189
|
|
Right-of-use assets
|
954
|
988
|
660
|
|
Goodwill
|
19,963
|
19,997
|
11,765
|
|
Intangible assets
|
41,265
|
42,387
|
20,347
|
|
Investments in associates and joint ventures
|
63
|
69
|
88
|
|
Other investments
|
1,174
|
1,168
|
972
|
|
Derivative financial instruments
|
87
|
102
|
115
|
|
Other receivables
|
864
|
895
|
549
|
|
Deferred tax assets
|
4,195
|
4,330
|
3,506
|
|
|
77,626
|
79,119
|
46,191
|
|
Current assets
|
|
|
|
|
Inventories
|
7,624
|
8,983
|
4,278
|
|
Trade and other receivables
|
8,683
|
9,644
|
6,281
|
|
Other investments
|
61
|
69
|
129
|
|
Derivative financial instruments
|
54
|
83
|
64
|
|
Intangible assets
|
96
|
105
|
-
|
|
Income tax receivable
|
367
|
663
|
347
|
|
Cash and cash equivalents
|
5,762
|
6,329
|
7,636
|
|
Assets held for sale
|
-
|
368
|
-
|
|
|
22,647
|
26,244
|
18,735
|
|
Total assets
|
100,273
|
105,363
|
64,926
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
(2,069)
|
(1,660)
|
(2,042)
|
|
Lease liabilities
|
(225)
|
(233)
|
(216)
|
|
Trade and other payables
|
(17,864)
|
(18,938)
|
(17,370)
|
|
Derivative financial instruments
|
(35)
|
(79)
|
(16)
|
|
Provisions
|
(1,423)
|
(768)
|
(875)
|
|
Income tax payable
|
(1,124)
|
(916)
|
(994)
|
|
|
(22,740)
|
(22,594)
|
(21,513)
|
|
Non-current liabilities
|
|
|
|
|
Interest-bearing loans and borrowings
|
(28,081)
|
(28,134)
|
(17,410)
|
|
Lease liabilities
|
(724)
|
(754)
|
(464)
|
|
Derivative financial instruments
|
(47)
|
(45)
|
(1)
|
|
Deferred tax liabilities
|
(5,626)
|
(6,206)
|
(2,823)
|
|
Retirement benefit obligations
|
(1,991)
|
(2,454)
|
(2,545)
|
|
Provisions
|
(949)
|
(956)
|
(576)
|
|
Other payables
|
(3,756)
|
(4,933)
|
(5,148)
|
|
|
(41,174)
|
(43,482)
|
(28,967)
|
|
Total liabilities
|
(63,914)
|
(66,076)
|
(50,480)
|
|
Net assets
|
36,359
|
39,287
|
14,446
|
|
Equity
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
Share capital
|
387
|
387
|
328
|
|
Share premium account
|
35,131
|
35,126
|
7,976
|
|
Other reserves
|
2,050
|
2,045
|
2,037
|
|
Retained earnings
|
(1,228)
|
1,710
|
4,089
|
|
|
36,340
|
39,268
|
14,430
|
|
Non-controlling interests
|
19
|
19
|
16
|
|
Total equity
|
36,359
|
39,287
|
14,446
|
Table 18: Condensed consolidated statement of changes in
equity
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 Jan 2021
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
|
Profit for the period
|
-
|
-
|
-
|
1,561
|
1,561
|
1
|
1,562
|
|
Other comprehensive loss
|
-
|
-
|
-
|
(55)
|
(55)
|
(1)
|
(56)
|
|
Transfer to other reserves
|
-
|
-
|
13
|
(13)
|
-
|
-
|
-
|
|
Transactions with owners:
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(2,490)
|
(2,490)
|
-
|
(2,490)
|
|
Issue of Ordinary Shares
|
-
|
5
|
-
|
-
|
5
|
-
|
5
|
|
Share-based payments charge for the period
|
-
|
-
|
-
|
82
|
82
|
-
|
82
|
|
Settlement of share plan awards
|
-
|
-
|
-
|
(295)
|
(295)
|
-
|
(295)
|
|
Net movement
|
-
|
5
|
13
|
(1,210)
|
(1,192)
|
-
|
(1,192)
|
|
At 31 Mar 2021
|
328
|
7,976
|
2,037
|
4,089
|
14,430
|
16
|
14,446
|
|
At 1 Jan 2022
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
|
Profit for the period
|
-
|
-
|
-
|
386
|
386
|
2
|
388
|
|
Other comprehensive income
|
-
|
-
|
-
|
19
|
19
|
(2)
|
17
|
|
Transfer to other reserves
|
-
|
-
|
5
|
(5)
|
-
|
-
|
-
|
|
Transactions with owners:
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,046)
|
(3,046)
|
-
|
(3,046)
|
|
Issue of Ordinary Shares
|
-
|
5
|
-
|
-
|
5
|
-
|
5
|
|
Share-based payments charge for the period
|
-
|
-
|
-
|
182
|
182
|
-
|
182
|
|
Settlement of share plan awards
|
-
|
-
|
-
|
(474)
|
(474)
|
-
|
(474)
|
|
Net movement
|
-
|
5
|
5
|
(2,938)
|
(2,928)
|
-
|
(2,928)
|
|
At 31 Mar 2022
|
387
|
35,131
|
2,050
|
(1,228)
|
36,340
|
19
|
36,359
|
Table 19: Condensed consolidated statement of cash
flows
|
For the quarter ended 31 March
|
2022
|
2021
|
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
|
Profit before tax
|
553
|
1,608
|
|
Finance income and expense
|
319
|
283
|
|
Share of after tax losses of associates and joint
ventures
|
6
|
4
|
|
Depreciation, amortisation and impairment
|
1,309
|
797
|
|
Decrease in working capital and short-term provisions
|
1,804
|
1,210
|
|
Gains on disposal of intangible assets
|
(10)
|
(310)
|
|
Gains on disposal of investments in associates and joint
ventures
|
-
|
(776)
|
|
Non-cash and other movements
|
(327)
|
(363)
|
|
Cash generated from operations
|
3,654
|
2,453
|
|
Interest paid
|
(194)
|
(187)
|
|
Tax paid
|
(228)
|
(332)
|
|
Net cash inflow from operating activities
|
3,232
|
1,934
|
|
Cash flows from investing activities
|
|
|
|
Payments upon vesting of employee share awards attributable to
business combinations
|
(55)
|
-
|
|
Payment of contingent consideration from business
combinations
|
(182)
|
(171)
|
|
Purchase of property, plant and equipment
|
(219)
|
(220)
|
|
Disposal of property, plant and equipment
|
-
|
4
|
|
Purchase of intangible assets
|
(144)
|
(249)
|
|
Disposal of intangible assets and assets held for sale
|
385
|
418
|
|
Purchase of non-current asset investments
|
(4)
|
-
|
|
Disposal of non-current asset investments
|
32
|
-
|
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
21
|
28
|
|
Payments to associates and joint ventures
|
(5)
|
(55)
|
|
Disposal of investments in associates and joint
ventures
|
-
|
776
|
|
Interest received
|
3
|
24
|
|
Net cash (outflow)/inflow from investing activities
|
(168)
|
555
|
|
Net cash inflow before financing activities
|
3,064
|
2,489
|
|
Cash flows from financing activities
|
|
|
|
Proceeds from issue of share capital
|
5
|
5
|
|
Repayment of loans and borrowings
|
(4)
|
(4)
|
|
Dividends paid
|
(2,971)
|
(2,469)
|
|
Hedge contracts relating to dividend payments
|
(77)
|
(23)
|
|
Repayment of obligations under leases
|
(74)
|
(50)
|
|
Movement in short-term borrowings
|
301
|
(190)
|
|
Payment of Acerta Pharma share purchase liability
|
(920)
|
-
|
|
Net cash outflow from financing activities
|
(3,740)
|
(2,731)
|
|
Net decrease in cash and cash equivalents in the
period
|
(676)
|
(242)
|
|
Cash and cash equivalents at the beginning of the
period
|
6,038
|
7,546
|
|
Exchange rate effects
|
(9)
|
(67)
|
|
Cash and cash equivalents at the end of the period
|
5,353
|
7,237
|
|
Cash and cash equivalents consist of:
|
|
|
|
Cash and cash equivalents
|
5,762
|
7,636
|
|
Overdrafts
|
(409)
|
(399)
|
|
|
5,353
|
7,237
|
Notes to the Interim Financial Statements
Note 1: Basis of preparation and accounting policies
These unaudited Interim Financial Statements for the three months
ended 31 March 2022 have been prepared in accordance with
UK-adopted International Accounting Standards and with the
requirements of the Companies Act 2006 as applicable to companies
reporting under those standards. The Interim Financial Statements
also comply fully with International Financial Reporting Standards
(IFRSs) as issued by the International Accounting Standards Board
(IASB) and International Accounting Standards as adopted by the
European Union.
The unaudited Interim Financial Statements for the three months
ended 31 March 2022 include Alexion's results for the period.
Alexion was consolidated into the Group's results from 21 July
2021, hence Alexion's results are not included in the comparative
periods shown.
The unaudited Interim Financial Statements for the three months
ended 31 March 2022 were approved by the Board of Directors for
publication on 29 April 2022.
The annual financial statements of the Group for the year ended 31
December 2021 were prepared in accordance with UK-adopted
International Accounting Standards and with the requirements of the
Companies Act 2006. The annual financial statements also comply
fully with IFRSs as issued by the IASB and International Accounting
Standards as adopted by the European Union. Except for the
estimation of the interim income tax charge, the Interim Financial
Statements have been prepared applying the accounting policies that
were applied in the preparation of the Group's published
consolidated financial statements for the year ended 31 December
2021.
The comparative figures for the financial year ended 31 December
2021 are not the Group's statutory accounts for that financial
year. Those accounts have been reported on by the Group's auditors
and will be delivered to the registrar of companies; their report
was (i) unqualified, (ii) did not include a reference to any
matters to which the auditors drew attention by way of emphasis
without qualifying their report, and (iii) did not contain a
statement under section 498(2) or (3) of the Companies Act
2006.
Global and/or geopolitical events
There were no material accounting impacts identified relating to
COVID-19 during the three months ended 31 March 2022.
The Group's current focus is to continue compliant business
operations in Russia and Ukraine, focussing on safeguarding our
employees, ensuring continuity of supply of essential and
life-saving medicines and contributing to humanitarian relief
efforts. There are no material accounting impacts arising from the
conflict impacting our Q1 2022 reporting. The situation is dynamic
and any future impact on our business is uncertain. We continue to
closely monitor the situation.
The Group will continue to monitor these areas of increased
judgement, estimation and risk for material changes.
Going concern
The Group has considerable financial resources available. As at 31
March 2022, the Group had $10.7bn in financial resources (cash and
cash-equivalent balances of $5.8bn and undrawn committed bank
facilities of $4.9bn available until April 2025, with only $2.3bn
of borrowings due within one year). All facilities contain no
financial covenants and were undrawn at 31 March 2022.
The Group's revenues are largely derived from sales of medicines
covered by patents which provide a relatively high level of
resilience and predictability to cash inflows, although government
price interventions in response to budgetary constraints are
expected to continue to affect adversely revenues in some of our
significant markets. The Group, however, anticipates new revenue
streams from both recently launched medicines and those in
development, and the Group has a wide diversity of customers and
suppliers across different geographic areas.
Consequently, the Directors believe that, overall, the Group is
well-placed to manage its business risks successfully.
Accordingly, the going concern basis has been adopted in these
Interim Financial Statements.
Legal proceedings
The information contained in Note 5 updates the disclosures
concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form
20-F Information 2021.
Note 2: Intangible assets
In accordance with IAS 36 ÔImpairment of Assets', reviews for
triggers at an individual asset or cash-generating-unit level were
conducted, and impairment tests carried out where triggers were
identified. As a result, total net impairment reversals of $94m
have been recorded against intangible assets during the three
months ended 31 March 2022 (Q1 2021: $55m charge). Net impairment
reversals in respect of medicines in development and launched
medicines were $77m (Q1 2021: $nil) and $nil (Q1 2021: $55m charge)
respectively.
Note 3: Net Debt
The table below provides an analysis of Net Debt and a
reconciliation of Net Cash Flow to the movement in Net Debt. The
Group monitors Net Debt as part of its capital-management policy as
described in Note 28 of the Annual Report and Form
20-F Information 2021. Net Debt
is a non-GAAP financial measure.
Table 20: Net Debt
|
|
At 1 Jan 2022
|
Cash flow
|
Non-cash& other
|
Exchange movements
|
At 31 Mar 2022
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(28,134)
|
-
|
6
|
47
|
(28,081)
|
|
Non-current instalments of leases
|
(754)
|
-
|
21
|
9
|
(724)
|
|
Total long-term debt
|
(28,888)
|
-
|
27
|
56
|
(28,805)
|
|
Current instalments of loans
|
(1,273)
|
4
|
5
|
-
|
(1,264)
|
|
Current instalments of leases
|
(233)
|
70
|
(66)
|
4
|
(225)
|
|
Commercial paper
|
-
|
(256)
|
-
|
-
|
(256)
|
|
Bank collateral
|
(93)
|
12
|
-
|
-
|
(81)
|
|
Other short-term borrowings excluding overdrafts
|
(3)
|
(57)
|
-
|
1
|
(59)
|
|
Overdrafts
|
(291)
|
(123)
|
-
|
5
|
(409)
|
|
Total current debt
|
(1,893)
|
(350)
|
(61)
|
10
|
(2,294)
|
|
Gross borrowings
|
(30,781)
|
(350)
|
(34)
|
66
|
(31,099)
|
|
Net derivative financial instruments
|
61
|
66
|
(68)
|
-
|
59
|
|
Net borrowings
|
(30,720)
|
(284)
|
(102)
|
66
|
(31,040)
|
|
Cash and cash equivalents
|
6,329
|
(553)
|
-
|
(14)
|
5,762
|
|
Other investments - current
|
69
|
(10)
|
-
|
2
|
61
|
|
Cash and investments
|
6,398
|
(563)
|
-
|
(12)
|
5,823
|
|
Net Debt
|
(24,322)
|
(847)
|
(102)
|
54
|
(25,217)
|
Non-cash movements in the period include fair-value adjustments
under IFRS 9.
The Group has agreements with some bank counterparties whereby the
parties agree to post cash collateral on financial derivatives, for
the benefit of the other, equivalent to the market valuation of the
derivative positions above a predetermined threshold. The carrying
value of such cash collateral held by the Group was $81m (31
December 2021: $93m) and the carrying value of such cash collateral
posted by the Group was $64m (31 December 2021: $47m). Cash
collateral posted by the Group is presented within Cash and cash
equivalents.
The equivalent GAAP measure to Net Debt is Ôliabilities
arising from financing activities', which excludes the amounts for
cash and overdrafts, other investments and non-financing
derivatives shown above and includes the Acerta Pharma share
purchase liability of $1,564m (31 December 2021: $2,458m), $824m of
which is shown in current other payables and $740m is shown in
non-current other payables.
Net Debt increased by $895m in the year to date to $25,217m.
Details of the committed undrawn bank facilities are disclosed
within the going concern section of Note 1.
During the three months to 31 March 2022, there were no changes to
the Company's solicited credit ratings issued by Standard and
Poor's (long term: A-; short term: A-2) and from Moody's (long
term: A3; short term: P-2).
Note 4: Financial Instruments
As detailed in the Group's most recent annual financial statements,
the principal financial instruments consist of derivative financial
instruments, other investments, trade and other receivables, cash
and cash equivalents, trade and other payables, lease liabilities
and interest-bearing loans and borrowings.
All fair value gains and/or losses that are presented in Net
gains/(losses) on equity investments measured at fair value through
other comprehensive income in the Condensed consolidated statement
of comprehensive income for the three months ending 31 March 2022
are Level 1 fair value measurements.
Financial instruments measured at fair value include $1,235m of
other investments, $4,175m held in money-market funds, $308m of
loans designated at fair value through profit or loss and $59m of
derivatives as at 31 March 2022. The total fair value of
interest-bearing loans and borrowings at 31 March 2022, which have
a carrying value of $31,099m in the Condensed consolidated
statement of financial position, was $31,902m.
Table 21: Financial instruments - contingent
consideration
|
|
|
2022
|
2021
|
|
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
|
2,544
|
321
|
2,865
|
3,323
|
|
Settlements
|
|
(173)
|
(9)
|
(182)
|
(171)
|
|
Disposals
|
|
-
|
(121)
|
(121)
|
-
|
|
Discount unwind
|
|
41
|
1
|
42
|
55
|
|
At 31 March
|
|
2,412
|
192
|
2,604
|
3,207
|
Contingent consideration arising from business combinations is
fair-valued using decision-tree analysis, with key inputs including
the probability of success, consideration of potential delays and
the expected levels of future revenues.
The contingent consideration balance relating to BMS's share of the
global diabetes alliance of $2,412m (31 December 2021:
$2,544m) would increase/decrease by $241m with an increase/decline
in sales of 10%, as compared with the current
estimates.
Note 5: Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered
typical to its business, including litigation and investigations
relating to product liability, commercial disputes, infringement of
intellectual property (IP) rights, the validity of certain patents,
anti-trust law and sales and marketing practices. The matters
discussed below constitute the more significant developments since
publication of the disclosures concerning legal proceedings in the
Company's Annual Report and Form 20-F Information 2021 (the
Disclosures). Unless noted otherwise below or in the Disclosures,
no provisions have been established in respect of the claims
discussed below.
As discussed in the Disclosures, the majority of claims involve
highly complex issues. Often these issues are subject to
substantial uncertainties and, therefore, the probability of a
loss, if any, being sustained and/or an estimate of the amount of
any loss is difficult to ascertain.
Unless specifically identified below that a provision has been
taken, AstraZeneca considers each of the claims to represent a
contingent liability and discloses information with respect to the
nature and facts of the cases in accordance with IAS
37.
There is one matter concerning legal proceedings in the
Disclosures, which is considered probable that an outflow will be
required, but for which we are unable to make an estimate of the
possible loss or range of possible losses at this
stage.
In cases that have been settled or adjudicated, or where
quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able
to make a reasonable estimate of the loss, AstraZeneca records the
loss absorbed or makes a provision for its best estimate of the
expected loss. The position could change over time and the
estimates that the Company made, and upon which the Company have
relied in calculating these provisions are inherently imprecise.
There can, therefore, be no assurance that any losses that result
from the outcome of any legal proceedings will not exceed the
amount of the provisions that have been booked in the accounts. The
major factors causing this uncertainty are described more fully in
the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and
enforce, its IP.
Matters disclosed in respect of the fourth quarter of 2021 and to
29 April 2022
Patent litigation
Enhertu
US patent proceedings
As previously disclosed, in October 2020, Seagen Inc. (Seagen)
filed a complaint against Daiichi Sankyo Company, Limited (Daiichi
Sankyo) in the US District Court for the Eastern District of Texas
alleging that Enhertu infringes US Patent No. 10,808,039 (the
Ô039 patent). AstraZeneca
co-commercialises Enhertu with Daiichi Sankyo, Inc. in the US. The
trial took place in April 2022. The jury found that the Ô039
patent was infringed and awarded Seagen $41.82m in past damages.
The parties await the schedules for a bench trial on equitable
issues and for consideration of post-trial
motions.
As previously disclosed, in December 2020 and January 2021,
AstraZeneca and Daiichi Sankyo filed post-grant review petitions
with the US Patent and Trademark Office (USPTO) alleging, inter
alia, that the Ô039 patent is invalid for lack of written
description and enablement. The USPTO initially declined to
institute the post-grant reviews, but in April 2022, the USPTO
granted the rehearing requests, instituting both post-grant review
petitions. An oral hearing is scheduled for January 2023 and a
decision is expected by April 2023.
Imfinzi
US patent proceedings
In March 2022, Bristol-Myers Squibb Co. and E.R. Squibb & Sons,
LLC filed a lawsuit in US District Court for the District of
Delaware against AstraZeneca alleging that AstraZeneca's marketing
of Imfinzi infringes several of their patents. No trial
date has been scheduled.
Patent proceedings outside the US
In February 2022, Ono Pharmaceuticals filed a lawsuit in Tokyo
District Court, Civil Division against AstraZeneca alleging that
AstraZeneca's marketing of Imfinzi in Japan infringes several of their patents.
No trial date has been scheduled.
Symbicort
US patent proceedings
As previously disclosed, AstraZeneca is involved in ongoing ANDA
patent litigation with Mylan Pharmaceuticals Inc. (Mylan) and
Kindeva Drug Delivery L.P. (Kindeva) brought in the US District
Court for the Northern District of West Virginia (the District
Court). In March 2022, the US Court of Appeals for the Federal
Circuit (the Federal Circuit) denied AstraZeneca's Combined
Petition for Panel Rehearing and Rehearing En Banc of the Federal
Circuit's December 2021 decision and the case was remanded back to
the District Court for further proceedings. In April 2022, the
District Court entered a Stipulation and Order dismissing patent
infringement claims related to various asserted patents and
otherwise narrowing the issues for trial. A trial in the matter is
scheduled to commence in May 2022.
In April 2022, AstraZeneca filed another ANDA action against Mylan
and Kindeva in the District Court asserting patent
infringement.
Tagrisso
US patent proceedings
In February 2020, in response to Paragraph IV notices from multiple
ANDA filers, AstraZeneca filed patent infringement lawsuits in the
US District Court for the District of Delaware. In its complaint,
AstraZeneca alleged that a generic version
of Tagrisso, if approved and marketed, would infringe a US
Orange Book-listed Tagrisso patent. In the fourth quarter of 2021,
AstraZeneca entered into settlement agreements with Zydus
Pharmaceuticals (USA) Inc., Cadila Healthcare Limited, MSN
Laboratories Pvt. Ltd., and MSN Pharmaceuticals Inc. In April 2022,
AstraZeneca entered into a settlement agreement with Alembic
Pharmaceuticals Limited. These settlements resolve all US patent
litigation between the parties relating to Tagrisso.
Patent proceedings outside the US
In Russia, in October 2021, AstraZeneca filed a lawsuit in the
Arbitration Court of the Moscow Region against Axelpharm, LLC to
prevent it from obtaining authorisation to market a generic version
of Tagrisso prior to the expiration of AstraZeneca's
patents covering Tagrisso. The lawsuit also names the Ministry of Health of
the Russian Federation as a third party. In March 2022, the court
dismissed the lawsuit, and AstraZeneca has filed an
appeal.
Ultomiris
As previously disclosed, Chugai Pharmaceutical Co., Ltd. (Chugai)
filed lawsuits against Alexion in the Delaware District Court as
well as in Tokyo District Court, alleging
that Ultomiris infringed US and Japanese patents held by
Chugai.
In March 2022, Alexion entered into a settlement agreement with
Chugai that resolves all patent disputes between the two companies
related to Ultomiris.
In accordance with the settlement agreement, Alexion and Chugai
have taken steps to withdraw patent infringement proceedings filed
with US District Court for the District of Delaware and Tokyo
District Court. Under the terms of the agreement, Alexion will make
a single payment of $775m in the second quarter of 2022, for which
a related charge was recognised through the non-core P&L in the
first quarter of 2022. No further amounts are payable by either
party.
Product liability litigation
Onglyza and Kombiglyze
In the US, AstraZeneca is defending various lawsuits alleging heart
failure, cardiac injuries, and/or death from treatment
with Onglyza or Kombiglyze. In February 2018, the Judicial Panel on
Multidistrict Litigation ordered the transfer of various pending
federal actions to the US District Court for the Eastern District
of Kentucky (the District Court) for consolidated pre-trial
proceedings with the federal actions pending in the District Court.
In the previously disclosed California State Court coordinated
proceeding, AstraZeneca's motion for summary judgment was granted
in March 2022. A motion for summary judgment is pending in the
District Court.
Commercial litigation
Pay Equity Litigation (US)
AstraZeneca is defending a putative class and collective action
matter in the US District Court for the Northern District of
Illinois brought by three named plaintiffs, who are former
AstraZeneca pharmaceutical sales representatives. The case involves
claims under the federal and Illinois Equal Pay Acts, with the
plaintiffs alleging they were paid less than male employees who
performed substantially similar and/or equal work. The plaintiffs
seek various damages on behalf of themselves and the putative class
and/or collective, including without limitation backpay, liquidated
damages, compensatory and punitive damages, attorneys' fees, and
interest.
The Court has not set a trial date and no class or collective
certification has been sought or granted as of this
time.
Government investigations/proceedings
COVID-19 Vaccine Supply and Manufacturing Inquiries
As previously disclosed, in June 2021, Argentina's Federal Criminal
Prosecutor's Office (the Prosecutor) contacted AstraZeneca
Argentina seeking documents and electronic records in connection
with a local criminal investigation relating to the public
procurement and supply of Vaxzevria in that country. In October 2021, the
Prosecutor filed a submission with the presiding court requesting
dismissal of the criminal investigation, and that request was
granted by the court in February 2022. This matter is now closed.
In February 2022, a Brazilian Public Prosecutor filed a lawsuit
against several defendants including the Brazilian Federal
Government, AstraZeneca, and other COVID-19 vaccine manufacturers.
In April 2022, a Brazilian Court issued an order dismissing the
lawsuit.
US 340B Litigations and Proceedings
As previously disclosed, AstraZeneca is involved in several matters
relating to its contract pharmacy recognition policy under the 340B
Drug Pricing Program in the US. AstraZeneca has sought to intervene
in three lawsuits against several US government agencies and their
officials relating to the appropriate interpretation of the
governing statute for the 340B Drug Pricing Program. Two of the
three cases are currently stayed pending further proceedings and
the third case has been dismissed. Administrative Dispute
Resolution proceedings have also been initiated against AstraZeneca
before the US Health Resources and Services Administration.
As previously disclosed, in January 2021, AstraZeneca filed a
separate lawsuit in federal court in Delaware alleging that an
Advisory Opinion issued by the Department of Health and Human
Services violates the Administrative Procedure Act. In June 2021,
the Court found in favour of AstraZeneca, invalidating the Advisory
Opinion. Prior to the Court's ruling, however, in May 2021,
the US government issued new and separate letters to AstraZeneca
(and other companies) asserting that our contract pharmacy policy
violates the 340B statute. AstraZeneca amended the complaint to
include allegations challenging the letter sent in May, and in
February 2022, the Court ruled in favour of AstraZeneca
invalidating those letters sent by the US Government. The US
government has appealed the decision.
Table 22: Q1 2022 - Product Sales year-on-year
analysis[75]
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% Change
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
Oncology
|
3,388
|
14
|
18
|
895
|
17
|
19
|
1,374
|
17
|
650
|
13
|
21
|
469
|
4
|
12
|
|
Tagrisso
|
1,304
|
14
|
17
|
406
|
32
|
33
|
439
|
6
|
252
|
12
|
21
|
207
|
2
|
11
|
|
Imfinzi
|
599
|
8
|
11
|
58
|
2
|
3
|
315
|
8
|
125
|
15
|
23
|
101
|
4
|
12
|
|
Lynparza
|
617
|
14
|
17
|
121
|
39
|
43
|
270
|
7
|
160
|
8
|
16
|
66
|
22
|
32
|
|
Calquence
|
414
|
98
|
n/m
|
7
|
n/m
|
n/m
|
339
|
74
|
55
|
n/m
|
n/m
|
13
|
n/m
|
n/m
|
|
Enhertu
|
11
|
n/m
|
n/m
|
6
|
n/m
|
n/m
|
-
|
-
|
4
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
|
Orpathys
|
13
|
n/m
|
n/m
|
13
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Zoladex
|
240
|
9
|
12
|
167
|
22
|
23
|
4
|
(19)
|
34
|
(9)
|
(3)
|
35
|
(18)
|
(9)
|
|
Faslodex
|
93
|
(24)
|
(20)
|
44
|
3
|
6
|
5
|
(41)
|
17
|
(59)
|
(56)
|
27
|
(8)
|
-
|
|
Iressa
|
32
|
(47)
|
(47)
|
27
|
(50)
|
(50)
|
2
|
(16)
|
1
|
(48)
|
(44)
|
2
|
(35)
|
(30)
|
|
Arimidex
|
32
|
(27)
|
(25)
|
25
|
(30)
|
(29)
|
-
|
51
|
1
|
(56)
|
(56)
|
6
|
(7)
|
1
|
|
Casodex
|
21
|
(48)
|
(47)
|
13
|
(59)
|
(59)
|
-
|
n/m
|
-
|
(24)
|
(24)
|
8
|
(10)
|
(1)
|
|
Others
|
12
|
1
|
6
|
8
|
3
|
7
|
-
|
n/m
|
1
|
49
|
61
|
3
|
(29)
|
(24)
|
|
BioPharmaceuticals: CVRM*
|
2,207
|
14
|
17
|
1,025
|
8
|
11
|
522
|
7
|
482
|
31
|
40
|
178
|
28
|
37
|
|
Farxiga
|
1,000
|
60
|
67
|
391
|
50
|
54
|
193
|
48
|
318
|
83
|
97
|
98
|
66
|
78
|
|
Brilinta
|
325
|
(13)
|
(10)
|
69
|
(35)
|
(32)
|
166
|
-
|
76
|
(13)
|
(6)
|
14
|
(5)
|
(1)
|
|
Lokelma
|
63
|
92
|
97
|
3
|
n/m
|
n/m
|
39
|
62
|
6
|
n/m
|
n/m
|
15
|
n/m
|
n/m
|
|
Roxadustat
|
41
|
6
|
4
|
41
|
6
|
4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Andexxa*
|
33
|
13
|
14
|
-
|
-
|
-
|
24
|
(7)
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Crestor
|
267
|
(2)
|
-
|
197
|
4
|
6
|
18
|
(16)
|
11
|
(48)
|
(44)
|
41
|
(2)
|
6
|
|
Seloken/Toprol-XL
|
244
|
(2)
|
(1)
|
238
|
(2)
|
(1)
|
-
|
n/m
|
4
|
13
|
7
|
2
|
(7)
|
-
|
|
Bydureon
|
68
|
(34)
|
(33)
|
1
|
60
|
63
|
57
|
(34)
|
10
|
(28)
|
(23)
|
-
|
(92)
|
(91)
|
|
Onglyza
|
68
|
(33)
|
(31)
|
34
|
(42)
|
(40)
|
18
|
(2)
|
11
|
(31)
|
(26)
|
5
|
(45)
|
(44)
|
|
Others
|
98
|
(15)
|
(13)
|
51
|
5
|
7
|
7
|
(58)
|
37
|
(20)
|
(19)
|
3
|
(27)
|
(20)
|
|
BioPharmaceuticals: R&I
|
1,509
|
(2)
|
-
|
437
|
(19)
|
(19)
|
645
|
17
|
277
|
(7)
|
(1)
|
150
|
-
|
5
|
|
Symbicort
|
674
|
(2)
|
-
|
167
|
1
|
3
|
259
|
(2)
|
157
|
(7)
|
-
|
91
|
(1)
|
3
|
|
Fasenra
|
308
|
18
|
22
|
7
|
n/m
|
n/m
|
189
|
22
|
75
|
20
|
29
|
37
|
(5)
|
2
|
|
Pulmicort
|
217
|
(34)
|
(34)
|
164
|
(43)
|
(43)
|
22
|
26
|
18
|
11
|
20
|
13
|
24
|
28
|
|
Breztri
|
87
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
53
|
n/m
|
5
|
n/m
|
n/m
|
7
|
46
|
59
|
|
Saphnelo
|
11
|
n/m
|
n/m
|
-
|
-
|
-
|
11
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Daliresp
|
51
|
(16)
|
(16)
|
1
|
(28)
|
(25)
|
47
|
(13)
|
3
|
(45)
|
(41)
|
-
|
6
|
7
|
|
Bevespi
|
15
|
15
|
14
|
2
|
51
|
30
|
11
|
10
|
2
|
16
|
24
|
-
|
24
|
35
|
|
Others
|
146
|
(9)
|
(9)
|
74
|
(3)
|
(4)
|
53
|
47
|
17
|
(62)
|
(60)
|
2
|
(53)
|
(51)
|
|
BioPharmaceuticals: V&I
|
1,757
|
n/m
|
n/m
|
630
|
n/m
|
n/m
|
386
|
n/m
|
286
|
15
|
22
|
455
|
n/m
|
n/m
|
|
Vaxzevria
|
1,089
|
n/m
|
n/m
|
475
|
n/m
|
n/m
|
79
|
n/m
|
135
|
(40)
|
(37)
|
400
|
n/m
|
n/m
|
|
Evusheld
|
469
|
n/m
|
n/m
|
89
|
n/m
|
n/m
|
307
|
n/m
|
65
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
|
Synagis
|
200
|
n/m
|
n/m
|
66
|
n/m
|
n/m
|
-
|
(97)
|
87
|
n/m
|
n/m
|
47
|
-
|
-
|
|
FluMist
|
(1)
|
n/m
|
n/m
|
-
|
(98)
|
(98)
|
-
|
n/m
|
(1)
|
n/m
|
n/m
|
-
|
(4)
|
(2)
|
|
Rare Disease*
|
1,694
|
3
|
7
|
115
|
(12)
|
3
|
1,020
|
7
|
361
|
-
|
8
|
198
|
1
|
10
|
|
Soliris*
|
990
|
(5)
|
-
|
71
|
(41)
|
(28)
|
591
|
7
|
221
|
(15)
|
(8)
|
107
|
4
|
11
|
|
Ultomiris*
|
419
|
20
|
25
|
24
|
n/m
|
n/m
|
220
|
6
|
105
|
54
|
65
|
70
|
(4)
|
7
|
|
Strensiq*
|
208
|
5
|
7
|
9
|
65
|
68
|
161
|
3
|
19
|
(1)
|
6
|
19
|
7
|
19
|
|
Koselugo
|
39
|
82
|
85
|
5
|
n/m
|
n/m
|
30
|
43
|
4
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Kanuma*
|
38
|
9
|
15
|
6
|
42
|
59
|
18
|
8
|
12
|
(1)
|
7
|
2
|
10
|
15
|
|
Other medicines
|
425
|
(19)
|
(15)
|
204
|
(31)
|
(29)
|
39
|
(24)
|
36
|
(31)
|
(28)
|
146
|
19
|
30
|
|
Nexium
|
332
|
(18)
|
(13)
|
144
|
(38)
|
(36)
|
33
|
4
|
15
|
(17)
|
(11)
|
140
|
17
|
28
|
|
Others
|
93
|
(22)
|
(22)
|
60
|
(4)
|
(4)
|
6
|
(71)
|
21
|
(39)
|
(37)
|
6
|
n/m
|
n/m
|
|
Total Product Sales
|
10,980
|
51
|
56
|
3,306
|
28
|
30
|
3,986
|
76
|
2,092
|
36
|
46
|
1,596
|
83
|
97
|
Table 23: Collaboration Revenue
|
|
|
Q1 2022
|
Q1 2021
|
|
|
|
$m
|
$m
|
|
Lynparza: regulatory
milestones
|
|
175
|
-
|
|
Enhertu: share of gross
profits
|
|
75
|
38
|
|
Royalty income
|
|
73
|
18
|
|
Tralokinumab: sales milestones
|
|
70
|
-
|
|
Other Ongoing Collaboration Revenue
|
|
17
|
7
|
|
Total
|
|
410
|
63
|
Table 24: Other Operating Income and Expense
|
|
|
Q1 2022
|
Q1 2021
|
|
|
|
$m
|
$m
|
|
Brazikumab licence termination funding
|
|
35
|
26
|
|
Divestment of Viela Bio, Inc. shareholding
|
|
-
|
776
|
|
Crestor (Europe ex-UK and
Spain)
|
|
-
|
309
|
|
Other
|
|
62
|
69
|
|
Total
|
|
97
|
1,180
|
Other shareholder information
Financial calendar
Announcement of half year and second quarter results
29
July 2022
Announcement of year to date and third quarter results
10 November
2022
Announcement of full year and fourth quarter
results
9 February 2023 (tentative)
Dividends are normally be paid as follows:
First interim:
Announced with the half-year and second-quarter results and paid in
September
Second interim: Announced with full-year and
fourth-quarter results and paid in March
The record date for the first interim dividend for 2022, payable on
12 September 2022, will be 12 August 2022. The ex-dividend date
will be 11 August 2022.
Contacts
For details on how to contact the Investor Relations Team,
please click
here. For Media
contacts, click
here
Addresses for correspondence
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
|
|
+44 (20 3749 5000
|
0800 389 1580
|
+46 (8 402 9000
|
+1 (88697 8018
|
|
|
+44 (121 415 7033
|
|
+1 (71921 8137
|
|
|
|
|
db@astfinancial.com
|
Trademarks
Trademarks of the AstraZeneca group of companies appear throughout
this document in italics. Medical publications also appear
throughout the document in italics. AstraZeneca, the AstraZeneca
logotype and the AstraZeneca symbol are all trademarks of the
AstraZeneca group of companies. Trademarks of companies other than
AstraZeneca that appear in this document
include Arimidex and Casodex,
owned by AstraZeneca or JuvisŽ (depending on
geography); Duaklir and Eklira, trademarks of Almirall,
S.A.; Enhertu, a trademark of Daiichi
Sankyo; Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd
(depending on geography); Synagis, owned by AstraZeneca or AbbVie Inc. (depending
on geography); and Tezspire, a trademark of Amgen, Inc.
Information on or accessible through AstraZeneca's websites,
including www.astrazeneca.com astrazeneca.com,
does not form part of and is not incorporated into this
announcement.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Cautionary statements regarding forward-looking
statements
In order, among other things, to utilise the 'safe harbour'
provisions of the US Private Securities Litigation Reform Act of
1995, AstraZeneca (hereafter Ôthe Group') provides the
following cautionary statement:
This document contains certain forward-looking statements with
respect to the operations, performance and financial condition of
the Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group's
control, include, among other things:
‒ the
risk of failure or delay in delivery of pipeline or launch of new
medicines
‒ the
risk of failure to meet regulatory or ethical requirements for
medicine development or approval
‒ the
risk of failures or delays in the quality or execution of the
Group's commercial strategies
‒ the
risk of pricing, affordability, access and competitive
pressures
‒ the
risk of failure to maintain supply of compliant, quality
medicines
‒ the
risk of illegal trade in the Group's medicines
‒ the
impact of reliance on third-party goods and
services
‒ the
risk of failure in information technology or
cybersecurity
‒ the
risk of failure of critical processes
‒ the
risk of failure to collect and manage data in line with legal and
regulatory requirements and strategic
objectives
‒ the
risk of failure to attract, develop, engage and retain a diverse,
talented and capable workforce
‒ the
risk of failure to meet regulatory or ethical expectations on
environmental impact, including climate change
‒ the
risk of the safety and efficacy of marketed medicines being
questioned
‒ the
risk of adverse outcome of litigation and/or governmental
investigations
‒ intellectual
property-related risks to our products
‒ the
risk of failure to achieve strategic plans or meet targets or
expectations
‒ the
risk of failure in financial control or the occurrence of
fraud
‒ the
risk of unexpected deterioration in the Group's financial
position
‒ the
impact that global and/or geopolitical events such as the COVID-19
pandemic and the Russia-Ukraine war, may have or continue to have
on these risks, on the Group's ability to continue to mitigate
these risks, and on the Group's operations, financial results or
financial condition
Nothing in this document, or any related presentation/webcast,
should be construed as a profit forecast.
- End of document -
[29] A breast cancer gene
mutation.
[30] Systemic lupus
erythematosus.
[31] Non-small cell lung
cancer.
[32] Chronic lymphocytic
leukaemia.
[33] Real-Time Oncology
Review.
[34] Chronic kidney
disease.
[35] Heart failure with
preserved ejection fraction.
[36] Hereditary amyloid
transthyretin polyneuropathy.
[37] Interim analysis, as
disclosed by Ionis Pharmaceuticals, Inc.
[38] Eosinophilic
oesophagitis.
[39] Epidermal growth
factor receptor mutation.
[40] Mantle cell
lymphoma.
[41] Triple negative
breast cancer.
[42] Chronic
rhinosinusitis with nasal polyps.
[43] Eosinophilic granulomatosis with
polyangiitis.
[44] Sales of medicines
through managed care and other channels are subject to rebates,
discounts, return fees, etc. An estimate of the likely levels
of these items is subtracted from the gross (or total) sales of a
medicine in order to establish the net product sales.
A gross-to-net
adjustment corrects any
divergence between the actual and prior estimated level of rebate,
discount or fee, once those items are known.
[45] Extensive stage
non-small cell lung cancer.
[46] Poly ADP ribose
polymerase.
[47] Homologous
recombination repair gene mutation.
[48] MesenchymalÐepithelial
transition.
[49] Sodium-glucose
co-transporter-2.
[50] European Society of
Cardiology.
[51] American Heart
Association.
[52] American College of
Cardiology.
[53] Urine albumin
creatine ratio.
[54] Meaured renal
function.
[55] Type-2
diabetes.
[56] Betaloc is the brand name
for Seloken in China.
[57] Dipeptidyl peptidase
IV.
[58] Other Operating
Income.
[59] Core financial
measures are adjusted to exclude certain items. For more
information on the Reported to Core financial adjustments, please
refer to the Operating and financial review.
[60] Based on best
prevailing assumptions around currency
profiles.
[61] Based on average
daily spot rates in FY 2021.
[62] Based on average
daily spot rates from 1 January 2022 to 31 March
2022.
[63] Other currencies
include AUD, BRL, CAD, KRW and RUB.
[64] An immune checkpoint
receptor.
[65] Radiographic progression-free
survival.
[66] Metastatic
castration-resistant prostate cancer.
[67] Homologous
recombination repair.
[68] Hazard
ratio.
[69] Overall
survival.
[70] Progression-free survival.
[71] Supplemental
Biologics License Application.
[72] Low-density
lipoprotein cholesterol.
[73] Complete response
letter.
[74] Lower respiratory
tract infections.
[75] The table provides an
analysis of year-on-year Product Sales, with Actual and CER growth
rates reflecting year-on-year growth. Due to rounding, the sum of a
number of dollar values and percentages may not agree to totals. *
FY 2022 Q1 growth rates on medicines acquired with Alexion have
been calculated on a pro forma basis comparing to the corresponding
period in the prior year, pre-acquisition as previously published
by Alexion. The growth rates shown for Rare Disease and CVRM
disease area totals include these pro forma
adjustments.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
29 April 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|